It is made available under a CC-BY-NC-ND 4.0 International license .

- 1 Competing Health Risks Associated with the COVID-19 Pandemic and Early Response: A
- 2 Scoping Review
- 3

4 Stefan Baral¹, Amrita Rao¹, Jean Olivier Twahirwa Rwema¹, Carrie Lyons¹, Muge Cevik², Anna

- 5 E. Kågesten³, Daouda Diouf⁴, Annette H. Sohn⁵, Nancy Phaswana-Mafuya⁶, Adeeba
- 6 Kamarulzaman⁷, Gregorio Millett⁸, Julia L. Marcus⁹, Sharmistha Mishra¹⁰
- 7

8 Author Affiliations

- 9 1) Department of Epidemiology, Johns Hopkins School of Public Health, Baltimore, MD
- 10 2) Division of Infection and Global Health Research, School of Medicine, University of St.
- 11 Andrews, Scotland
- 12 3) Department of Global Public Health, Karolinska Institutet, Sweden
- 13 4) Enda Santé, Dakar, Senegal
- 14 5) TREAT Asia, amfAR, the Foundation for AIDS Research, Bangkok, Thailand
- 15 6) Department of Environmental Health, Faculty of Health Sciences, University of
- 16 Johannesburg
- 17 7) University of Malaya, Kuala Lumpur, Malaysia
- 18 8) Public Policy Office, amfAR, Washington DC
- 19 9) Department of Population Medicine, Harvard Medical School and Harvard Pilgrim
- 20 Health Care Institute, Boston, MA
- 21 10) Li Ka Shing Knowledge Institute, St. Michael's Hospital, University of Toronto, Toronto,
 22 Canada
- 23

24 **Disclosures**

- 25 Annette Sohn and Gregorio Millett report funding from ViiV Healthcare. Julia Marcus has
- 26 consulted in the past for Kaiser Permanente Northern California on a research grant from Gilead
- 27 Sciences. All other authors report no competing interests.
- 28

29 Funding

- 30 Amrita Rao is supported in part by the National Institute of Mental Health [F31MH124458].
- 31 Julia Marcus is supported in part by the National Institute of Allergy and Infectious Diseases
- 32 [K01AI122853]. Sharmistha Mishra is supported by a Tier 2 Canada Research Chair in
- 33 Mathematical Modeling.
- 34

35 License

- The Corresponding Author grants on behalf of all authors, a worldwide license to publishers andlicensees for this work.
- 3/ licensees for this work
- 38

39 Author Contributions

- 40 The article was conceptualized by SB, AR, JOT, and CL. SB led manuscript development. AR,
- 41 JOTR, CL led the literature reviews with AR synthesizing literature for HIV, JOT for
- 42 malnutrition, CL for malaria, MC for tuberculosis, and AEK for selected sexual and reproductive
- 43 health outcomes. AHS led writing of global research agenda, GM on policy, and SM on
- 44 mathematical modeling. AEK, DD, RPM, and JM drafted other sections of the manuscript. All
- 45 authors reviewed and agreed upon the final version of the manuscript. This assessment
- 46 represents the views of the authors and not official positions of their employers.

It is made available under a CC-BY-NC-ND 4.0 International license .

47

- 48 Words: 4738
- 49 Abstract
- 50 Background
- 51 COVID-19 has rapidly emerged as a global public health threat with infections recorded in
- 52 nearly every country. Responses to COVID-19 have varied in intensity and breadth, but
- 53 generally have included domestic and international travel limitations, closure of non-essential
- 54 businesses, and repurposing of health services. While these interventions have focused on
- testing, treatment, and mitigation of COVID-19, there have been reports of interruptions to
- 56 diagnostic, prevention, and treatment services for other public health threats.
- 57

58 **Objectives**

- 59 We conducted a scoping review to characterize the early impact of COVID-19 on HIV,
- 60 tuberculosis, malaria, sexual and reproductive health, and malnutrition.
- 61

69

62 Methods

- 63 A scoping literature review was completed using searches of PubMed and preprint servers
- 64 (medRxiv/bioRxiv) from January 1st to October 31st, 2020, using Medical Subject Headings
- 65 (MeSH) terms related to SARS-CoV-2 or COVID-19 and HIV, tuberculosis, malaria, sexual and
- 66 reproductive health, and malnutrition. Empiric studies reporting original data collection or
- 67 mathematical models were included, and available data synthesized by region. Studies were
- 68 excluded if they were not written in English.

70 **Results**

- 71 A total of 1604 published papers and 205 preprints met inclusion criteria, including 8.2%
- 72 (132/1604) of published studies and 10.2% (21/205) of preprints: 7.3% (68/931) on HIV, 7.1%
- 73 (24/339) on tuberculosis, 11.6% (26/224) on malaria, 7.8% (13/166) on sexual and reproductive
- health, and 9.8% (13/132) on malnutrition. Thematic results were similar across competing
- 75 health risks, with substantial indirect effects of the COVID-19 pandemic and response on
- 76 diagnostic, prevention, and treatment services for HIV, tuberculosis, malaria, sexual and
- 77 reproductive health, and malnutrition.
- 78

79 **Discussion**

- 80 COVID-19 emerged in the context of existing public health threats that result in millions of
- 81 deaths every year. Thus, effectively responding to COVID-19 while minimizing the negative
- 82 impacts of COVID-19 necessitates innovation and integration of existing programs that are often
- 83 siloed across health systems. Inequities have been a consistent driver of existing health threats;
- 84 COVID-19 has worsened disparities, reinforcing the need for programs that address structural
- 85 risks. The data reviewed here suggest that effective strengthening of health systems should
- 86 include investment and planning focused on ensuring the continuity of care for both rapidly
- 87 emergent and existing public health threats.
- 88
- 89
- 90
- 91
- 92

It is made available under a CC-BY-NC-ND 4.0 International license .

93 Introduction

94

95 The coronavirus disease 2019 (COVID-19) pandemic is among the most significant public health 96 emergencies of international concern over the last hundred years causing substantial morbidity 97 and mortality worldwide [1]. Public health responses to COVID-19 have varied in intensity, 98 breadth, and duration, but in many countries have included domestic and international travel 99 restrictions, stay-at-home orders and curfews, closure of non-essential businesses and schools, 100 and repurposing of health services [2]. Although the goals of these interventions are to mitigate 101 transmission of SARS-CoV-2 and ensure sufficient capacity for testing and treatment, such 102 measures also have broader social, economic, and health impacts, including disruptions to 103 routine public health programs and other clinical services [3-7]. Even when prevention or 104 treatment services have remained uninterrupted, some people have been unwilling to seek care at 105 healthcare facilities because of concerns about nosocomial SARS-CoV-2 acquisition risk or the 106 misconception that services are only available for patients with COVID-19[8]. 107 Taken together, COVID-19 may have profound indirect and longer-term effects on broader 108 health outcomes, including morbidity and mortality associated with other infectious and 109 noncommunicable diseases. Moreover, there may be increased risks of indirect health effects of 110 the COVID-19 pandemic in low- and middle-income countries because of suboptimal healthcare 111 resources and infrastructure. Within all countries, existing socioeconomic inequities, driven in 112 part by structural racism, are likely to shape who is most affected, both directly and indirectly, by 113 COVID-19. Marginalized groups that already experienced inadequate access to prevention, 114 diagnostic, and treatment services, as well as a higher prevalence of other health conditions, may 115 be most profoundly impacted by further interruptions to prevention, diagnostic, and treatment 116 services during the pandemic response.[9] Understanding the indirect effects of COVID-19 on

It is made available under a CC-BY-NC-ND 4.0 International license .

117 health services, overall health outcomes, and equity is critical for planning and adapting public

118 health responses to emerging infections, which need to maximize control of outbreaks while

119 minimizing setbacks in other areas of health.

120 The objective of this review was to characterize the impact of early mitigation measures for the

121 COVID-19 pandemic on health conditions that cause significant morbidity and mortality,

122 including services and outcomes related to HIV infection, tuberculosis (TB), malaria, sexual and

123 reproductive health (SRH), and malnutrition. To that end, we used a scoping rather than

124 systematic review to summarize research findings and reporting from a range of different data

sources and study types [10]. The results of the scoping review are synthesized, including

126 implications for global health investments and policies that can mitigate the indirect effects of

127 COVID-19 and future public health emergencies of international concern.

128

129 Methods

130 We conducted a scoping review of published papers and preprints through October 31, 2020.

131 Search strategies (Appendix) were developed using MeSH and key terms to focus on COVID-19

132 and its impact on one of the pre-specified key competing health risks: HIV, TB, malaria, SRH

133 (contraceptives, abortion, pregnancy-related and newborn care), and malnutrition. Abstracts and

134 full-text articles were reviewed using Covidence[11], an online systematic review management

tool, and EndNote (version X8) [12].

136 For published papers, searches were implemented in PubMed. For preprints, we conducted a

137 search of the COVID-19 Living Evidence Database, which includes published papers and

138 preprints from both medRxiv and bioRxiv and is updated daily

139 (https://zika.ispm.unibe.ch/assets/data/pub/search_beta/).

It is made available under a CC-BY-NC-ND 4.0 International license .

140 Articles were eligible for inclusion if the primary focus was the impact of COVID-19 on one of 141 the five listed public health threats, and if they included empiric data or mathematical models on 142 health or service outcomes. We excluded articles not written in English. Commentaries were 143 screened for key themes to support interpretation of the measured and modeled data. Articles 144 were included if they were published or posted between November 2019 and October 2020 with 145 the most recent search implemented on October 31, 2020. 146 Titles and abstracts were reviewed by a single reviewer and selected for inclusion in this review 147 based on the above criteria. The reviewers of each of the sections were as follows: HIV (AR), 148 TB (CL), malaria (CL), SRH (JOTR), and malnutrition (JOTR). Table 1 depicts the number of 149 articles pulled, formally included based on the inclusion criteria, designated as commentaries, 150 and excluded. Included articles were reviewed and an initial scan was completed for available 151 empiric data or mathematical models and themes in terms of epidemiology of the burden or 152 associated mortality of the condition and changes to service delivery. Some key indicators 153 included changes in new infections and coverage of prevention and treatment services. 154 Following this initial scan, calibration meetings were held in order to refine data charting 155 processes, and final charting and synthesis were done independently. 156

157 **Results**

158 **Outcomes of the Scoping Review**

The systematic search identified a total of 1604 published papers and 205 preprints. For articles related to the impact of COVID-19 on the HIV pandemic, 7.3% (68/931) were deemed relevant and included in this review, along with 7.1% (24/339) for TB, 11.6% (26/224) for malaria, 7.8%

It is made available under a CC-BY-NC-ND 4.0 International license .

162 (13/166) for SRH, and 9.8% (13/132) for malnutrition. The number of selected papers that were

163 screened and eligible are reported in **Table 1**.

164 Summary of Charted Results

165 It was found that COVID-19 has been associated with reduced access to services, decreased

166 diagnosis, and poorer health outcomes for HIV, TB, malaria, and SRH, and increases in

167 malnutrition.

168 COVID-19 Impact on HIV Services

169 Three main themes emerged from a review of the literature related to the potential impact of 170 COVID-19 on HIV. The majority of papers included in this review described a destabilization of 171 HIV service delivery and the negative impact of COVID-19 mitigation efforts on HIV testing, 172 access to care, and viral suppression.[13, 14] Across geographic contexts, including in Australia, 173 Indonesia, Italy, Kenya, and Uganda, fewer people living with HIV reported being able to attend 174 clinic visits and access antiretroviral therapy (ART), resulting in a decline in the number of 175 people estimated to be virally suppressed [15-19]. For example, in a global survey of men who 176 have sex with men (MSM), close to 20% (218/1105) reported being unable to access their HIV

177 provider during the pandemic and half reported being unable to refill their HIV prescription

178 remotely (820/1254).[18] In terms of HIV prevention, there was a decline in the number of

people being tested and diagnosed [15, 20-22] and the amount of pre-exposure prophylaxis

180 (PrEP) [23, 24] and post-exposure prophylaxis dispensed[18, 25, 26], although these declines

181 may have been attributable in part to reductions in sexual activity [23, 24]. For example, one

182 study of 847 gay and bisexual men in Australia found that about 42% discontinued PrEP use

183 during the COVID-19 pandemic and that those discontinuing were less likely to report casual

sexual partners [23]. COVID-19 responses have resulted in interruptions to the supply chains for

It is made available under a CC-BY-NC-ND 4.0 International license .

185 the distribution of both ART and PrEP, and stock-outs of medications, as one study from

186 Indonesia described.[16]

187	Disparities were also identified in who was affected by interruptions to HIV prevention and
188	treatment services. Specifically, existing socioeconomic inequities, including reduced access to
189	health insurance and unstable housing, were associated with HIV service interruptions.[14, 27]
190	In addition, key populations-including MSM, female sex workers, people who use drugs, and
191	transgender populations-that depend on services from community-based organizations because
192	of stigma within the health sector may have been particularly vulnerable to disruptions in
193	outreach services caused by shelter-in-place mandates [28-30].
194	In some settings, there were reported adaptations in the implementation of HIV service delivery
195	to mitigate interruptions, including adoption of telemedicine [19, 31-36]; home-based HIV
196	testing and self-testing[37-39]; home or mobile delivery of ART[34, 35, 40]; use of curbside
197	pickup (i.e. pickup of supplies without stepping out of a vehicle) for condoms, lubricants, and
198	medications[41]; and designation of surrogates such as peers to motivate and support ongoing
199	treatment.[19] Adaptation of clinical services benefited from training of providers and
200	approaches that promoted trust and took into consideration patients' needs and preferences.[32]
201	Access to non-medical support, including cash transfers, reimbursement for the costs associated
202	with accessing care,[19] and housing and food supplementation support were key to promoting
203	ongoing engagement in care.[29, 39] However, medical support and telemedicine strategies
204	alone were unlikely to fully mitigate the poorer HIV outcomes observed; one study from a
205	safety-net HIV clinic in San Francisco found that the odds of viral non-suppression were 31%
206	higher after a shelter-in place mandate compared to before the mandate, even with telemedicine

It is made available under a CC-BY-NC-ND 4.0 International license .

207 services.[14] Notably, most studies describing adaptations were in higher-income settings,

208 though this may be reflective of a publication bias.

209 COVID-19 Impact on TB Care Cascade

210 Over the past several years, TB incidence and mortality have been steadily declining because of

211 improvements in diagnosis, treatment, and prevention. The data available to date suggest that

212 COVID-19 has resulted in disruptions that may challenge the WHO goal to end the TB pandemic

213 by 2030.

214 Reductions in timely diagnosis and treatment of new TB cases have resulted from COVID-19-

215 related disruptions to access to healthcare services and availability of diagnostic capacity.

216 Overwhelmed healthcare systems have often de-prioritized TB testing in laboratories and

217 diverted these resources to COVID-19 testing [42]. In South Africa and Nigeria, for instance,

218 GeneXpert machines and kits were prioritized for COVID-19 testing, leading to a drop of more

than 50% in the median number of daily GeneXpert TB tests[43, 44]. Social distancing

220 measures implemented in many countries disrupted patients' access to care, which impeded

diagnosis, initiation of appropriate treatment, and follow-up. In Bangladesh, Kenya, Nigeria and

222 Pakistan, the ability of residents in lower-income communities—which have a higher risk of

223 TB—to seek healthcare for TB services has been reduced during COVID-19-related

restrictions[45]. Missed diagnoses increase opportunities for transmission, while worsened

treatment outcomes increase the risk of TB-related morbidity and mortality.

There have also been documented interruptions to services for people diagnosed with TB [46,

47]. For instance, in early 2020, there had been a substantial reduction in TB notifications in

228 China, India, Japan, Nigeria, the Philippines, Sierra Leone, South Korea, and the United States

compared with the same period in previous years [48-57]. Specifically, there was a decline of

It is made available under a CC-BY-NC-ND 4.0 International license .

230	more than 50% in TB notifications in China in 2020 compared to 2015–2019.[58] Furthermore,
231	in Nigeria and South Korea, there was a one-third decrease in the number of active TB
232	notifications in 2020 compared with prior years. As restrictive measures were lifted and COVID-
233	19 rates declined, most of these settings reported an increase in TB notification rates [48-57]. In
234	addition, reduced access to healthcare services and re-deployment of the TB workforce for the
235	management of COVID-19 [59, 60] have created conditions for low adherence to treatment,
236	which might also contribute to ongoing transmission and the emergence and spread of drug-
237	resistant TB. During COVID-19-related restrictions in China, patient treatment completion and
238	screening for drug-resistant TB among new and high-risk TB patients declined by approximately
239	20% [48].
240	At a broader level, COVID-19 prevention and mitigation measures have increased poverty and
241	undernutrition, which are major risk factors for the acquisition and active conversion of TB. In
242	India, an estimated 140 million people have lost their jobs during COVID-19 [61]. In Brazil, the
243	regions hardest hit by COVID-19 largely overlap with the regions where higher TB rates are
244	observed [62]. With increased poverty and undernutrition, TB cases may surge among these
245	disadvantaged communities. Furthermore, as regular services continue to be disrupted, routine
246	TB immunization programs have been affected, such as in Pakistan, where an over 40% decline
247	in BCG vaccinations has been reported [63].
248	Multiple modelling studies have estimated that COVID-19-related disruptions and fragmentation
249	of TB services could result in an increase in TB incidence and mortality[64, 65]. The Stop TB
250	Partnership reported that without countermeasures to maintain TB services, a 3-month period of
251	COVID-19 restrictions followed by a 10-month recovery period could lead to an additional 6.3
252	million cases of TB by 2025 and an additional 1.4 million TB-related deaths in low- and middle-

It is made available under a CC-BY-NC-ND 4.0 International license .

253 income countries [66]. Another modelling study estimated that over the next 5 years, these deaths 254 could increase by up to 20%[67]. This emphasizes that the adverse effects of short-term 255 disruptions will need to be addressed through "catch-up" TB case detection and treatment 256 programs[68]. Critical efforts to mitigate impacts on TB control could include integration of TB 257 and COVID-19 services for infection control, contact tracing, community-based care, 258 surveillance, and monitoring. Innovative ways to deliver medicines and collect specimens for 259 follow-up TB testing at home, and combine screening for TB and COVID-19, have already been 260 demonstrated in South Africa [40, 69]. The socioeconomic inequities driving both TB and 261 COVID-19 highlight the need for all countries to invest in universal health coverage and ensure 262

equitable access to services.

263 **COVID-19 Impact on Malaria Services**

264 Studies have collectively demonstrated challenges in maintaining malaria prevention and control 265 efforts in the context of COVID-19. In a study of 106 countries, 73% of malaria programs 266 reported disruptions to service delivery, of which 19% reported high or very high levels of 267 disruptions, potentially leading to increased morbidity and mortality.[70, 71] A resurgence of 268 malaria due to COVID-19 may occur overall, and especially among vulnerable young children 269 and pregnant women. [72-74] Of particular concern is the disruption of prevention efforts, 270 including routine distribution of long-lasting insecticide-treated nets, seasonal malaria 271 chemoprevention, and indoor residual spraying of insecticide. [72, 75] A modeling study 272 suggested that the greatest impact on malaria burden could result from interruption of planned 273 bed net campaigns, predicting 36% more deaths over 5 years in high-burden settings than would have occurred without COVID-19-related disruptions.[67] Another mathematical model 274 275 suggested that COVID-19-related disruptions to malaria chemoprevention efforts and

It is made available under a CC-BY-NC-ND 4.0 International license .

distribution of insecticide-treated nets in sub-Saharan Africa may have contributed to a doublingof malaria-related mortality in 2020.[76]

278 Malaria diagnoses during the COVID-19 outbreak have decreased, with a reduction in the

notification rate as high as 62% in some settings.[77, 78] This reduction in diagnoses may be due

280 to several factors, including reductions in health-seeking behavior related to malaria, as

individuals may be reluctant to visit health facilities due to COVID-19.[72, 77] Conversely,

282 healthcare providers previously focused on delivering malaria care may have been reassigned to

work on COVID-19, therefore limiting available malaria diagnostic services. COVID-19 and

284 malaria have overlapping symptoms, including fever, difficulty breathing, headaches, and body

pain, and there may be misdiagnosis of these infections in the context of limited laboratory

testing.[79, 80] Furthermore, delays in reporting of malaria testing and confirmed cases have

287 been observed, possibly due to disruptions in surveillance reporting structures.[77] Overall,

undetected malaria infections as a result of the focus on COVID-19 testing threaten malaria

control efforts.[81]

290 Chloroquine (CQ) and its derivative, hydroxychloroquine (HCQ), are established prophylactic

and clinical treatments for malaria and widely used in endemic areas. Early in the COVID-19

292 pandemic, these antimalarials were considered for potential treatment of COVID-19, and the

293 U.S. FDA issued a temporary emergency use authorization for the use of HCQ for treatment of

294 COVID-19, which was then rescinded in June 2020.[82] Across settings, there was a

295 documented increase in prescriptions of antimalarials, including an 80-fold increase in HCQ

296 prescriptions in the U.S.[82] [83] Indiscriminate and widespread prophylactic and therapeutic

use of CQ and HCQ for COVID-19 may complicate malaria prevention and control through

several mechanisms. Alongside the increase in demand, shortages in the immediate supply may

It is made available under a CC-BY-NC-ND 4.0 International license .

reduce their availability for use in malaria prevention and control, especially in low- and middleincome settings, which rely on international supply chains.[84, 85] Importantly, resistance to CQ
and HCQ has previously emerged, and further indiscriminate use due to COVID-19 may drive
Plasmodium resistance in malaria-endemic areas and threaten malaria control. [74, 81, 83, 86]

303 **COVID-19 Impact on Sexual and Reproductive Health Services**

304 In terms of the impact on SRH, we focused on early disruptions in selected essential services, 305 including contraceptives, abortion, and pregnancy-related and newborn care [87]. Other SRH 306 services and outcomes (e.g., screening, prevention, and care related to sexually transmitted 307 infections, sexual violence, and reproductive cancers) were beyond the scope of our review. 308 Early during the COVID-19 outbreak, Robertson et al.[88] estimated that a 10-52% drop in 309 service coverage would result in 12,000-57,000 additional maternal deaths over a 6-month period 310 in low- and middle-income countries. Similarly, Riley et al predicted that a 10% decline in SRH 311 services would add 15.4 million unintended pregnancies, 3.3 million unsafe abortions, and 312 28,000 additional maternal deaths on a yearly basis [89]. Studies conducted during the initial 313 phases of the pandemic outbreak and response further highlight SRH-related service disruptions, 314 including 60 million fewer contraceptive users. These numbers are highest in Sub-Saharan 315 Africa, Latin America, and the Caribbean, where the prevalence of provider-administered 316 methods requiring face-to-face contact (such as injectable contraception) is the highest [90, 91]. 317 Social distancing measures have resulted in interruptions to commodity production, supply chain 318 delays, and clinic closures, resulting in commodity shortages.[92] In India, Marie Stopes 319 International reported serving 1.3 million fewer women with contraceptive and abortion services 320 than expected.[93] At the time the current search was conducted, research studies had 321 documented mixed results in terms of the impact of COVID-19 on SRH service delivery

It is made available under a CC-BY-NC-ND 4.0 International license .

322 outcomes [94-96]. Decreases in access to and use of contraceptives, antenatal care, safe abortion, 323 and institutional delivery have been documented across different health systems and income 324 contexts, including Kenya, [97, 98] Ethiopia, [99] Turkey, [100] Italy, [101], UK, [102] and the 325 US.[103-105] Notably, a recent large-scale prospective observational study in Nepal found a 326 52% decrease in institutional births coupled with increased neonatal mortality rates and poor 327 intrapartum care during COVID-19-related restrictions [106]. 328 Frontline maternal health workers have described changed care practices globally, such as 329 relocation of human resources to the COVID-19 response, reduced face-to-face consultations, 330 visitor bans (including for partners), and shorter post-delivery stays for mothers and infants [107-331 113]. Several adaptations have been introduced to mitigate the effects of these health systems 332 challenges [114], including the Kenyan "Wheels for life initiative" to provide free transportation 333 services to pregnant women during curfew hours.[97] "click and collect" access to 334 contraceptives, [115] and increased transition to telemedicine [111, 114-117]. In particular, 335 newly imposed abortion restrictions in a number of European countries[118] and the US[103, 336 104, 119] during the initial COVID-19 outbreak have created an increased demand for medical abortion via telemedicine in several countries [118, 120-123]. This has been authorized in the 337 338 UK in order to ensure equity and continuity or abortion care during COVID-19 [118]. However, 339 technology requirements and legal restrictions on abortions mean that many women who need 340 these adapted services will not be able to access them [120, 123]. These programs and 341 workarounds highlight a demand for self-care services that will likely persist or grow in the 342 future [124].

343 COVID-19 Impact on Nutrition Services

It is made available under a CC-BY-NC-ND 4.0 International license .

344 The immediate effect of COVID-19 on nutrition has been an increase in the number of 345 individuals facing food insecurity in low-, middle-, and high-income countries [125, 126]. Food 346 insecurity appears to be related to disruption of food supply chains due to limited movements of 347 people and goods between countries, which in turn caused a disruption of food markets, 348 increased food waste, and inflation of food prices.[127-129] This disruption of markets was 349 exacerbated by the economic fallout associated with COVID-19, resulting in millions of people 350 losing their sources of income, particularly in low- and middle-income countries, where the 351 majority of individuals work in the informal sector. Though food insecurity has affected 352 individuals of all demographics, children and women of low socioeconomic status have been 353 particularly affected by service interruptions due to COVID-19, and the effects may be long-354 lasting among these populations. 355 School closures have resulted in loss of access to healthy foods for millions of school-aged

356 children and adolescents who relied on schools to access healthy meals [130-132]. In addition, 357 among children less than five years of age, malnutrition has been projected to increase, resulting 358 in substantial morbidity and mortality, especially among children [133]. For instance, a 359 modelling study focusing on 118 low- and middle-income countries (LMIC) estimated that the 360 disruptions in health services and increase food insecurity due to COVID-19 could result in a 361 14% increase in the prevalence of malnutrition, translating to 6.7 million more children under 362 five experiencing severe malnutrition. The same study estimated that COVID-19 would be 363 associated with more than 120,000 additional deaths among children under five because of 364 increased malnutrition and other unmet child health needs. Maternal mortality is also expected 365 to increase as a result of increased food insecurity and reduced access to maternal health 366 programs [133, 134]. Specifically, a separate modelling study estimated an additional 12,200 to

It is made available under a CC-BY-NC-ND 4.0 International license .

367 56,700 maternal deaths could occur as a result of disruption in maternal health and nutrition368 programs in LMIC [88].

369 Given the substantial negative effects on nutrition and the associated morbidity and mortality, 370 several papers have lamented the lack of explicit nutrition programs in the COVID-19 response 371 and called for integration of nutrition programs within COVID-19 mitigation strategies. Specific 372 strategies to mitigate increased malnutrition could include population-level interventions to 373 support the communities most vulnerable to malnutrition[135]. In Nepal, for example, specific 374 interventions to offset risks associated with restrictive COVID-19 interventions included 375 continuation of vitamin A supplementation and provision of deworming tablets to children, 376 programs supporting breastfeeding and other complementary foods, distribution of fortified 377 foods to pregnant women, and ensuring the continuity of other existing maternal and child 378 programs[134]. 379 In addition to food insecurity, there has been an increase in unhealthy eating habits since the start 380 of COVID-19. A cross-sectional study among over 1000 adult participants in Poland found that 381 43% of participants reported eating more frequently and 50% reporting more snacking. 382 Furthermore, 30% of participants in the study reported weight gain since the initiation of 383 COVID-19-related restrictions [136], while 15% of participants reported consuming more 384 alcohol and 45% of smokers reported increased smoking frequency. 385 Discussion

Across high-, middle-, and lower-income countries, COVID-19 has been associated with reduced access to services, decreased diagnosis, and poorer health outcomes for HIV, TB, malaria, and SRH, and increases in malnutrition. The most affected populations appear to be communities already on the margins, including those with lower income, racial and ethnic minorities, and

It is made available under a CC-BY-NC-ND 4.0 International license .

women, resulting in the amplification of existing health inequities. In 2015, all United Nations
Member States adopted the 2030 Agenda for Sustainable Development with a focus on 17
Sustainable Development Goals. To support health and wellbeing for all, the Sustainable
Development Goals laid out ambitious plans for zero new HIV, malaria, and TB infections by
2030, and ambitious goals to address malnutrition and reproductive health. Increases in
communicable diseases and malnutrition, worsened reproductive health outcomes, and widening
inequities could collectively result in a reversal of global health gains in key indicators[137].

398 The indirect effects of the COVID-19 pandemic may force a reexamination of global health 399 investments and policies. Specifically, it has been estimated that as much as 90% of countries 400 have experienced declines in per capita income due to the COVID-19 pandemic and responses 401 [138]. These decreases have prompted questions regarding the viability of the Sustainable 402 Development Goals and whether they should reflect more achievable targets in the wake of 403 programmatic disruptions due to COVID-19 [139]. In addition, as service disruptions and 404 COVID-19-related restrictions are expected to disproportionately affect already-marginalized 405 groups—such as adolescents, sexual and gender minority communities, people living with HIV, refugees and migrants, and people facing gender-based violence[89, 98, 140-142]-human-rights 406 407 affirming, intersectional approaches for monitoring and addressing the indirect effects on 408 programs are critical [18] [140]. Specific funding support to non-governmental organizations 409 with strong connections to these communities may be able to overcome disruptions in health 410 services during public health emergencies. Moreover, efforts to decriminalize marginalized 411 populations should be prioritized to promote legal and economic opportunities, as well as access 412 to health care. Finally, there have been calls for more resilient supply chains for medicine and

It is made available under a CC-BY-NC-ND 4.0 International license .

food in low- and middle-income countries. This requires supporting local market chains and
removing intellectual property barriers to and within those countries to avoid reliance on
international food and medicine supply chains and strengthen their production and delivery of
biofortified foods and pharmaceutical interventions. [128] The importance of local production of
pharmaceutical products including vaccines has been highlighted throughout COVID-19 given
the extreme inequities that have defined COVID-19 vaccine distribution, availability, and
ultimately, coverage.

420 Despite differences of opinion in specific policy actions, there are a few areas where a broad 421 consensus is emerging. Multilateral initiatives and commitments are more important than ever, 422 and donors must redouble their efforts to invest in global health efforts rather than retrench to 423 keep from losing decades of gains. COVID-19 has stressed the capacity of health systems 424 because of vertical and siloed health infrastructure designed to respond to specific diseases. 425 Integrated health systems can not only address a multiplicity of health issues, but also can 426 support integrated surveillance, data systems, supply chain management, and delivery[143]. To 427 inform these policy initiatives, there is a need for disease-specific approaches to shift towards 428 studying communities of individuals and health systems.

The benefits of scientific discovery are not linear with respect to disease. For instance, scientific advances in HIV have benefited cancer and hepatitis research, and have served as a basis for COVID-19 vaccines.[144, 145] Similarly, these health conditions themselves are interrelated. For instance, TB is the leading cause of death for people living with HIV in sub-Saharan Africa.[146] However, disease-specific research has often failed to study and respond to the complexities of this reality. Before COVID-19, for example, it would have been unusual to conduct research on the impact of a respiratory virus infection on domestic violence, depression,

It is made available under a CC-BY-NC-ND 4.0 International license .

and job security among women living with HIV who were diabetic. However, given anecdotal 436 437 and media reports of these relationships, research should evolve accordingly to better inform the 438 lived realities of the public. Cross-disciplinary research initiatives can characterize the direct and 439 indirect impacts of COVID-19, including implementation research on syndemic-related health 440 outcomes, effects of legal policies and increased policing (e.g., protections for marginalized 441 populations), structural racism, and issues of food security and employment.[147-150] In 442 addition, studies on optimizing resource allocation and supply chain management for 443 therapeutics and vaccines are critical to avoid worsening of inequities during scale-up.[151] To 444 respond to these needs, the WHO convened a Global Research Forum early in February 2020 to 445 accelerate research on the immediate priorities of COVID-19 mitigation and treatment, with 446 secondary aims to build up global research platforms and drive equitable access to diagnostics 447 and therapeutics.[117] Moreover, there was to be intentional assessment of how public health 448 strategies may impact a multitude of factors across physical and mental health, as well as social 449 infrastructure, economies, and politics.[152-154] 450 Mathematical models have played a significant role in COVID-19-related decision-making. As 451 in previous outbreaks and pandemics, transmission dynamics and statistical modelling provided 452 rapid estimates drawing on rapidly evolving information [155] [156]. Similar to the policy and 453 research initiatives to date, infectious disease modelling has remained largely "vertical", or 454 siloed by health threats, thus resembling and informing decision-making for vertical health 455 services. As models are expected to continue to drive decision making, the next generation of 456 pandemic preparedness models could integrate case projection for an emerging infectious 457 disease, and disease-specific health care and public health needs, with adaptive strategies for a 458 resilient health care system. In projecting how many acute care hospital beds might be needed to

It is made available under a CC-BY-NC-ND 4.0 International license .

care for patients with severe COVID-19, integration of other conditions could inform strategies 459 460 to manage the surges while also minimizing disruptions to other health care services. For 461 example, if estimates of the reduction in contact rates required to decrease SARS-CoV-2 spread 462 were integrated, a priori, decision-makers could better understand differential COVID-19 mitigation strategies alongside systems-level modelling to inform decision-making across health 463 464 services[157]. Separate from variability in underlying mortality, health system infrastructure 465 varies significantly across regions, including health and human services per population or in-466 hospital and intensive care beds per capita. Further integration of localized health infrastructure 467 parameters with COVID-19 transmission models would also support localized decision making 468 for optimal interventions [158-160].

469

470 There are several limitations of this scoping review. Given the breadth of information reviewed, 471 including over 1800 peer-reviewed and preprint articles, we did not conduct a formal population-472 intervention-control-outcome systematic review. In addition, the search strategy was only 473 implemented in PubMed, medrxiv, and biorxiv, which means we may have missed other articles 474 that were only indexed in other databases. Moreover, there were several areas not covered in this 475 review, including vaccine-preventable diseases[161], non-communicable diseases[162, 163], 476 specific health effects among migrant communities[164], violence[165], and mental health[166]. 477 The timing of this review includes a focus on 2020 representing the earlier phase of the 478 pandemic and early mitigation efforts though a non-systematic assessment in November, 2021 479 suggested that the trends reported were sustained. Preliminary data suggest effects across all 480 these areas, including reports of increased domestic violence, decreases in childhood 481 vaccinations, and increases in mortality and morbidity because of acute mental health stressors

medRxiv preprint doi: https://doi.org/10.1101/2021.01.07.21249419; this version posted December 15, 2021. The copyright holder for this preprint (which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. It is made available under a CC-BY-NC-ND 4.0 International license.

482 and substance use. In addition, publication bias may have affected the estimates reported here.

483 Because we did not complete a quantitative meta-analysis, we were unable to assess the

484 magnitude of publication bias. Finally, there may be limited generalizability of the indirect

485 effects of COVID-19 across regions given significant variability in the underlying causes of

486 morbidity and mortality and varying health systems and health infrastructure.

487 Conclusions

498

488 The COVID-19 pandemic has exposed disparate risks and inequities by income, race and

489 ethnicity, gender, and immigration status. The results of this scoping review demonstrate ways

490 that the COVID-19 pandemic and response have impacted other diseases and essential services,

491 risking decades of progress in outcomes associated with HIV, TB, malaria, sexual and

492 reproductive health, and malnutrition. Given vaccine inequity, the places most affected by these

493 conditions were also the least able to support the vaccination of their population—likely causing

494 even greater morbidity and mortality. Many settings have adapted by developing programs to

495 mitigate the indirect effects of COVID-19, but optimizing population-level health in the context

496 of public health emergencies of international concern necessitates broader innovation in research,

497 mathematical modeling, policy, and programs. Moreover, a cross-disciplinary research agenda

499 decision making for health care and public health systems by integrating counterfactuals ('what

for pandemic preparedness and response modelling offers an opportunity to examine optimal

500 if experiments) for one disease with those for other health conditions. COVID-19 responses

500 if' experiments) for one disease with those for other health conditions. COVID-19 responses

501 should also include a rights-based approach that helps ensure equitable access to prevention,

502 diagnostic, and treatment services for both COVID-19 and competing health risks. The redesign

503 and strengthening of health systems must include the strengthening of public health systems,

504 with adequate funding and planning to ensure continuity of contextually relevant health and

It is made available under a CC-BY-NC-ND 4.0 International license .

- social welfare programs that specifically address the needs of communities most socially and
- 506 economically marginalized.

- **Table 1.** Number of papers pulled, included, marked as relevant commentaries, and excluded by
- 518 competing health risk as part of the scoping review

PUBLISHED LITERATURE (PubMed)								
	HIV	Malaria	Malnutrition	SRH	ТВ			
Pulled	827	189	125	162	301			
Included	60	23	13	13	20			
Commentaries	43	24	27	60	58			
Excluded	724	165	82	89	223			

PREPRINTS (COVID-19 Living Evidence database)								
	HIV	Malaria	Malnutrition	SRH	ТВ			
Pulled	104	35	7	21	38			
Included	8	3	0	6	4			
Commentaries	0	0	0	0	1			
Excluded	96	32	7	15	33			

520 SRH=Sexual and Reproductive Health; TB=Tuberculosis

It is made available under a CC-BY-NC-ND 4.0 International license .

535 **References**

536

Dong E, Du H, Gardner L. An interactive web-based dashboard to track COVID-19 in
 real time. The Lancet Infectious Diseases. 2020;20(5):533-4. doi: 10.1016/S1473-

539 3099(20)30120-1.

540 2. Holland CE, Kouanda S, Lougue M, Pitche VP, Schwartz S, Anato S, et al. Using

541 Population-Size Estimation and Cross-sectional Survey Methods to Evaluate HIV Service

542 Coverage Among Key Populations in Burkina Faso and Togo. Public Health Rep.

- 543 2016;131(6):773-82. doi: 10.1177/0033354916677237. PubMed PMID: 28123223; PubMed
- 544 Central PMCID: PMCPMC5230836.
- 545 3. Kazi DS, Wadhera RK, Shen C, Ho KKL, Patell R, Selim MH, et al. Decline in Emergent
 546 and Urgent Care during the COVID-19 Pandemic. medRxiv. 2020:2020.05.14.20096602. doi:
 547 10.1101/2020.05.14.20096602.
- 548 4. Hartnett KP, Kite-Powell A, DeVies J, Coletta MA, Boehmer TK, Adjemian J, et al.
- 549 Impact of the COVID-19 Pandemic on Emergency Department Visits United States, January 1,
- 550 2019-May 30, 2020. MMWR Morb Mortal Wkly Rep. 2020;69(23):699-704. Epub 2020/06/12.
- doi: 10.15585/mmwr.mm6923e1. PubMed PMID: 32525856; PubMed Central PMCID:
- PMCPMC7315789 Journal Editors form for disclosure of potential conflicts of interest. No
 potential conflicts of interest were disclosed.
- 554 5. Hungerford D, Cunliffe NA. Coronavirus disease (COVID-19) impact on vaccine
- 555 preventable diseases. Euro Surveill. 2020;25(18). Epub 2020/05/14. doi: 10.2807/1560-556 7917.ES.2020.25.18.2000756. PubMed PMID: 32400359; PubMed Central PMCID:
- 557 PMCPMC7219030.
- 558 6. COVID-19 significantly impacts health services for noncommunicable diseases559 [Internet]. 2020
- 560 7. Mafham MM, Spata E, Goldacre R, Gair D, Curnow P, Bray M, et al. COVID-19
- 561 pandemic and admission rates for and management of acute coronary syndromes in England.
- 562 Lancet. 2020;396(10248):381-9. Epub 2020/07/18. doi: 10.1016/S0140-6736(20)31356-8.
- 563 PubMed PMID: 32679111; PubMed Central PMCID: PMCPMC7429983.
- 8. Mehrotra A, Chernew M, Linetsky D, Hatch H, Cutler D, Schneider EC. The Impact of
 the COVID-19 Pandemic on Outpatient Care: Visits Return to Prepandemic Levels, but Not for
 All Providers and Patients. Commonwealth Fund, 2020.
- 567 9. CDC. Health Equity Considerations and Racial and Ethnic Minority Groups 2020.
- 568 Available from: https://www.cdc.gov/coronavirus/2019-ncov/community/health-equity/race-569 ethnicity.html.
- 570 10. Tricco AC, Lillie E, Zarin W, O'Brien KK, Colquhoun H, Levac D, et al. PRISMA
 571 Extension for Scoping Reviews (PRISMA-ScR): Checklist and Explanation. Ann Intern Med.
- 572 2018;169(7):467-73. Epub 2018/09/05. doi: 10.7326/M18-0850. PubMed PMID: 30178033.
- 573 11. Covidence systematic review software, Veritas Health Innovation, Melbourne, Australia.
 574 2020. Available from: www.covidence.org.
- 575 12. EndNote X8. Clarivate Analytics 2020. Available from: https://endnote.com/.
- 576 13. Ridgway JP, Schmitt J, Friedman E, Taylor M, Devlin S, McNulty M, et al. HIV Care
- 577 Continuum and COVID-19 Outcomes Among People Living with HIV During the COVID-19
- 578 Pandemic, Chicago, IL. AIDS Behav. 2020;24(10):2770-2. doi: 10.1007/s10461-020-02905-2.
- 579 PubMed PMID: 32382823.

It is made available under a CC-BY-NC-ND 4.0 International license .

580 14. Spinelli MA, Hickey MD, Glidden DV, Nguyen JQ, Oskarsson JJ, Havlir D, et al. Viral 581 suppression rates in a safety-net HIV clinic in San Francisco destabilized during COVID-19. 582 Aids. 2020. doi: 10.1097/qad.00000000002677. PubMed PMID: 32910069. 583 15. Quiros-Roldan E, Magro P, Carriero C, Chiesa A, El Hamad I, Tratta E, et al. 584 Consequences of the COVID-19 pandemic on the continuum of care in a cohort of people living 585 with HIV followed in a single center of Northern Italy. AIDS Res Ther. 2020;17(1):59. doi: 586 10.1186/s12981-020-00314-y. PubMed PMID: 33012282. 587 Luis H, Fridayantara WD, Mahariski P, Wignall FS, Irwanto I, Gedela K. Evolving ART 16. 588 crisis for people living with HIV in Indonesia. Lancet HIV. 2020;7(6):e384-e5. doi: 589 10.1016/s2352-3018(20)30138-7. PubMed PMID: 32359421. 590 Linnemayr S, Jennings Mayo-Wilson L, Saya U, Wagner Z, MacCarthy S, Walukaga S, 17. 591 et al. HIV Care Experiences During the COVID-19 Pandemic: Mixed-Methods Telephone 592 Interviews with Clinic-Enrolled HIV-Infected Adults in Uganda. AIDS Behav. 2020:1-12. doi: 593 10.1007/s10461-020-03032-8. PubMed PMID: 32918641. 594 Rao A, Rucinski K, Jarrett B, Ackerman B, Wallach S, Marcus J, et al. Potential 18. 595 interruptions in HIV prevention and treatment services for gay, bisexual, and other men who 596 have sex with men associated with COVID-19. MedRxiv. 2020. doi: 597 10.1101/2020.08.19.20178285. 598 Nyoni T, Okumu M. COVID-19-Compliant Strategies for Supporting Treatment 19. 599 Adherence Among People Living with HIV in Sub-Saharan Africa. AIDS Behav. 600 2020;24(9):2473-6. doi: 10.1007/s10461-020-02888-0. PubMed PMID: 32333204. 601 Ponticiello M, Mwanga-Amumpaire J, Tushemereirwe P, Nuwagaba G, King R, 20. Sundararajan R. "Everything is a Mess": How COVID-19 is Impacting Engagement with HIV 602 603 Testing Services in Rural Southwestern Uganda. AIDS Behav. 2020;24(11):3006-9. doi: 604 10.1007/s10461-020-02935-w. PubMed PMID: 32451939. 605 21. Darcis G, Vaira D, Moutschen M. Impact of coronavirus pandemic and containment 606 measures on HIV diagnosis. Epidemiol Infect. 2020;148:e185. doi: 607 10.1017/s0950268820001867. PubMed PMID: 32829742. 608 22. Ejima K, Koizumi Y, Yamamoto N, Rosenberg M, Ludema C, Bento AI, et al. HIV 609 testing by public health centers and municipalities, and new HIV cases during the COVID-19 610 pandemic in Japan. MedRxiv. 2020. doi: 10.1101/2020.10.16.20213959. Hammoud MA, Grulich A, Holt M, Maher L, Murphy D, Jin F, et al. Substantial decline 611 23. 612 in use of HIV pre-exposure prophylaxis (PrEP) following introduction of COVID-19 physical 613 distancing restrictions in Australia: Results from a prospective observational study of gay and 614 bisexual men. J Acquir Immune Defic Syndr. 2020. doi: 10.1097/qai.00000000002514. 615 PubMed PMID: 33027151. 616 Chow EPF, Hocking JS, Ong JJ, Schmidt T, Buchanan A, Rodriguez E, et al. Changing 24. 617 the Use of HIV Pre-exposure Prophylaxis Among Men Who Have Sex With Men During the 618 COVID-19 Pandemic in Melbourne, Australia. Open Forum Infect Dis. 2020;7(7):ofaa275. doi: 10.1093/ofid/ofaa275. PubMed PMID: 32704518. 619 620 Sánchez-Rubio J, Vélez-Díaz-Pallarés M, Rodríguez González C, Sanmartin Fenollera P, 25. 621 García Yubero C, Fernández-Pacheco García-Valdecasas M. HIV postexposure prophylaxis 622 during the COVID-19 pandemic: experience from Madrid. Sex Transm Infect. 2020. doi:

623 10.1136/sextrans-2020-054680. PubMed PMID: 32680842.

It is made available under a CC-BY-NC-ND 4.0 International license .

624 26. Chow EPF, Hocking JS, Ong JJ, Phillips TR, Fairley CK. Postexposure prophylaxis 625 during COVID-19 lockdown in Melbourne, Australia. Lancet HIV. 2020;7(8):e528-e9. doi: 626 10.1016/s2352-3018(20)30204-6. PubMed PMID: 32687796. 627 27. Qiao S, Li Z, Weissman S, Li X, Olatosi B, Davis C, et al. Disparity in HIV Service 628 Interruption in the Outbreak of COVID-19 in South Carolina. AIDS Behav. 2020:1-9. doi: 629 10.1007/s10461-020-03013-x. PubMed PMID: 32856176. 630 28. Gichuna S, Hassan R, Sanders T, Campbell R, Mutonyi M, Mwangi P. Access to 631 Healthcare in a time of COVID-19: Sex Workers in Crisis in Nairobi, Kenya. Glob Public 632 Health. 2020;15(10):1430-42. doi: 10.1080/17441692.2020.1810298. PubMed PMID: 32816628. 633 29. Santos GM, Ackerman B, Rao A, Wallach S, Ayala G, Lamontage E, et al. Economic, 634 Mental Health, HIV Prevention and HIV Treatment Impacts of COVID-19 and the COVID-19 635 Response on a Global Sample of Cisgender Gay Men and Other Men Who Have Sex with Men. 636 AIDS Behav. 2020:1-11. doi: 10.1007/s10461-020-02969-0. PubMed PMID: 32654021. 637 30. Sanchez TH, Zlotorzynska M, Rai M, Baral SD. Characterizing the Impact of COVID-19 638 on Men Who Have Sex with Men Across the United States in April, 2020. AIDS Behav. 639 2020;24(7):2024-32. doi: 10.1007/s10461-020-02894-2. PubMed PMID: 32350773. 640 31. Rogers BG, Arnold T, Schierberl Scherr A, Strong SH, Holcomb R, Daley Ndoye C, et 641 al. Adapting Substance Use Treatment for HIV Affected Communities During COVID-19: 642 Comparisons Between a Sexually Transmitted Infections (STI) Clinic and a Local Community 643 Based Organization. AIDS Behav. 2020;24(11):2999-3002. doi: 10.1007/s10461-020-02933-y. 644 PubMed PMID: 32462344. 645 Mgbako O, Miller EH, Santoro AF, Remien RH, Shalev N, Olender S, et al. COVID-19, 32. 646 Telemedicine, and Patient Empowerment in HIV Care and Research. AIDS Behav. 647 2020;24(7):1990-3. doi: 10.1007/s10461-020-02926-x. PubMed PMID: 32440970. 648 Hoagland B, Torres TS, Bezerra DRB, Geraldo K, Pimenta C, Veloso VG, et al. 33. 649 Telemedicine as a tool for PrEP delivery during the COVID-19 pandemic in a large HIV 650 prevention service in Rio de Janeiro-Brazil. Braz J Infect Dis. 2020;24(4):360-4. doi: 651 10.1016/j.bjid.2020.05.004. PubMed PMID: 32504552. 652 34. Armstrong WS, Agwu AL, Barrette EP, Ignacio RB, Chang JJ, Colasanti JA, et al. 653 Innovations in HIV care delivery during the COVID-19 pandemic: Policies to strengthen the 654 Ending the Epidemic Initiative - A Policy Paper of the Infectious Diseases Society of America 655 and the HIV Medicine Association. Clin Infect Dis. 2020. doi: 10.1093/cid/ciaa1532. PubMed 656 PMID: 33035296. 657 Giuliani M, Donà MG, La Malfa A, Pasquantonio MS, Pimpinelli F, Cristaudo A, et al. 35. 658 Ensuring retention in care for people living with HIV during the COVID-19 pandemic in Rome, 659 Italy. Sex Transm Infect. 2020. doi: 10.1136/sextrans-2020-054650. PubMed PMID: 33046581. 660 36. Dourado I, Magno L, Soares F, Massa P, Nunn A, Dalal S, et al. Adapting to the COVID-661 19 Pandemic: Continuing HIV Prevention Services for Adolescents Through Telemonitoring, 662 Brazil. AIDS Behav. 2020;24(7):1994-9. doi: 10.1007/s10461-020-02927-w. PubMed PMID: 663 32440973. 664 Menza TW, Garai J, Ferrer J, Hecht J. Rapid Uptake of Home-Based HIV Self-testing 37. 665 During Social Distancing for SARS-CoV2 Infection in Oregon. AIDS Behav. 2020:1-4. doi: 666 10.1007/s10461-020-02959-2. PubMed PMID: 32594272. 667 Mhango M, Chitungo I, Dzinamarira T. COVID-19 Lockdowns: Impact on Facility-38. 668 Based HIV Testing and the Case for the Scaling Up of Home-Based Testing Services in Sub-

- 669 Saharan Africa. AIDS Behav. 2020;24(11):3014-6. doi: 10.1007/s10461-020-02939-6. PubMed 670 PMID: 32488551.
- 671 Odinga MM, Kuria S, Muindi O, Mwakazi P, Njraini M, Melon M, et al. HIV testing 39.
- 672 amid COVID-19: community efforts to reach men who have sex with men in three Kenyan
- 673 counties. Gates Open Res. 2020;4:117. doi: 10.12688/gatesopenres.13152.1. PubMed PMID:

674 32954217.

- 675 40. Brey Z, Mash R, Goliath C, Roman D. Home delivery of medication during Coronavirus
- 676 disease 2019, Cape Town, South Africa: Short report. Afr J Prim Health Care Fam Med.
- 2020;12(1):e1-e4. doi: 10.4102/phcfm.v12i1.2449. PubMed PMID: 32501022. 677
- 678 41. Kay ES, Musgrove K. From HIV to Coronavirus: AIDS Service Organizations 679 Adaptative Responses to COVID-19, Birmingham, Alabama. AIDS Behav. 2020;24(9):2461-2. 680 doi: 10.1007/s10461-020-02879-1. PubMed PMID: 32333206.
- 681 Mohammed H, Oljira L, Roba KT, Yimer G, Fekadu A, Manyazewal T. Containment of 42.
- 682 COVID-19 in Ethiopia and implications for tuberculosis care and research. Infectious Diseases 683 of Poverty. 2020;9(1):131. doi: 10.1186/s40249-020-00753-9.
- 684 Abdool Karim Q, Abdool Karim SS. COVID-19 affects HIV and tuberculosis care. 43. 685 Science. 2020;369(6502):366-8. Epub 2020/07/25. doi: 10.1126/science.abd1072. PubMed 686 PMID: 32703860.
- 687 Togun T, Kampmann B, Stoker NG, Lipman M. Anticipating the impact of the COVID-44. 688 19 pandemic on TB patients and TB control programmes. Annals of Clinical Microbiology and 689 Antimicrobials. 2020;19(1):21. doi: 10.1186/s12941-020-00363-1.
- 690 Ahmed SAKS, Ajisola M, Azeem K, Bakibinga P, Chen Y-F, Choudhury NN, et al. 45.
- 691 Impact of the societal response to COVID-19 on access to healthcare for non-COVID-19 health
- 692 issues in slum communities of Bangladesh, Kenya, Nigeria and Pakistan: results of pre-COVID
- 693 and COVID-19 lockdown stakeholder engagements. BMJ Global Health. 2020;5(8):e003042. 694 doi: 10.1136/bmjgh-2020-003042.
- Migliori GB, Thong PM, Akkerman O, Alffenaar J-W, Álvarez-Navascués F, Assao-695 46.
- 696 Neino MM, et al. Worldwide Effects of Coronavirus Disease Pandemic on Tuberculosis 697 Services, January–April 2020. Emerging Infectious Disease journal. 2020;26(11):2709. doi:
- 698 10.3201/eid2611.203163.
- Shen X, Sha W, Yang C, Pan Q, Cohen T, Chen S, et al. Continuity of services for 699 47.
- 700 patients with tuberculosis in China in the COVID-19 era. medRxiv. 2020:2020.07.16.20150292. 701 doi: 10.1101/2020.07.16.20150292.
- 702 Liu Q, Lu P, Shen Y, Li C, Wang J, Zhu L, et al. Collateral Impact of the Coronavirus 48.
- 703 Disease 2019 (COVID-19) Pandemic on Tuberculosis Control in Jiangsu Province, China. 704 Clinical Infectious Diseases. 2020. doi: 10.1093/cid/ciaa1289.
- 705 49.
- Kwak N, Hwang S-S, Yim J-J. Effect of COVID-19 on Tuberculosis Notification, South 706 Korea. Emerging Infectious Disease journal. 2020;26(10):2506. doi: 10.3201/eid2610.202782.
- 707 Adewole OO. Impact of COVID-19 on TB care: experiences of a treatment centre in 50.
- 708 Nigeria. Int J Tuberc Lung Dis. 2020;24(9):981-2. Epub 2020/11/07. doi: 10.5588/ijtld.20.0418.
- 709 PubMed PMID: 33156771.
- 710 Louie JK, Reid M, Stella J, Agraz-Lara R, Graves S, Chen L, et al. A decrease in 51.
- 711 tuberculosis evaluations and diagnoses during the COVID-19 pandemic. Int J Tuberc Lung Dis.
- 712 2020;24(8):860-2. Epub 2020/09/12. doi: 10.5588/ijtld.20.0364. PubMed PMID: 32912395.
- 713 52. Buonsenso D, Iodice F, Sorba Biala J, Goletti D. COVID-19 effects on tuberculosis care
- 714 in Sierra Leone. Pulmonology. 2020. doi: https://doi.org/10.1016/j.pulmoe.2020.05.013.

- 715 53. Chen H, Zhang K. Insight into the impact of the COVID-19 epidemic on tuberculosis
- burden in China. European Respiratory Journal. 2020;56(3):2002710. doi:
- 717 10.1183/13993003.02710-2020.
- 54. Chiang C-Y, Islam T, Xu C, Chinnayah T, Garfin AMC, Rahevar K, et al. The impact of
 COVID-19 and the restoration of tuberculosis services in the Western Pacific Region. European
 Pagningtony Journal 2020;56(4):2002054 doi: 10.1182/12002002.02054.2020
- 720 Respiratory Journal. 2020;56(4):2003054. doi: 10.1183/13993003.03054-2020.
- 55. Datta B, Jaiswal A, Goyal P, Prakash A, Tripathy JP, Trehan N. The untimely demise of
- the TB Free block model in the wake of coronavirus disease 2019 in India. Transactions of The
- Royal Society of Tropical Medicine and Hygiene. 2020;114(11):789-91. doi:
- 724 10.1093/trstmh/traa067.
- 725 56. Komiya K, Yamasue M, Takahashi O, Hiramatsu K, Kadota JI, Kato S. The COVID-19
- pandemic and the true incidence of Tuberculosis in Japan. J Infect. 2020;81(3):e24-e5. Epub
- 2020/07/11. doi: 10.1016/j.jinf.2020.07.004. PubMed PMID: 32650109; PubMed Central
 PMCID: PMCPMC7338857.
- 729 57. Lai CC, Yu WL. The COVID-19 pandemic and tuberculosis in Taiwan. J Infect.
- 730 2020;81(2):e159-e61. Epub 2020/06/14. doi: 10.1016/j.jinf.2020.06.014. PubMed PMID:
- 731 32534000; PubMed Central PMCID: PMCPMC7286835.
- 58. Liu Q, Lu P, Shen Y, Li C, Wang J, Zhu L, et al. Collateral Impact of the Covid-19
- 733 Pandemic on Tuberculosis Control in Jiangsu Province, China. Clin Infect Dis. 2020. Epub
- 734 2020/08/29. doi: 10.1093/cid/ciaa1289. PubMed PMID: 32857838; PubMed Central PMCID:
 735 PMCPMC7499510.
- 73659.Khan MS, Rego S, Rajal JB, Bond V, Fatima RK, Isani AK, et al. Mitigating the impact
- of COVID-19 on tuberculosis and HIV services: a cross-sectional survey of 669 health
- professionals in 64 low and middle-income countries. medRxiv. 2020:2020.10.08.20207969. doi:
 10.1101/2020.10.08.20207969.
- 60. Cronin AM, Railey S, Fortune D, Wegener DH, Davis JB. Notes from the Field: Effects
- of the COVID-19 Response on Tuberculosis Prevention and Control Efforts United States,
- 742 March-April 2020. MMWR Morb Mortal Wkly Rep. 2020;69(29):971-2. Epub 2020/07/24. doi:
- 743 10.15585/mmwr.mm6929a4. PubMed PMID: 32701944; PubMed Central PMCID:
- PMCPMC7377818 Journal Editors form for disclosure of potential conflicts of interest. Nopotential conflicts of interest were disclosed.
- 746 61. Husain AA, Monaghan TM, Kashyap RS. Impact of COVID-19 pandemic on
- tuberculosis care in India. Clin Microbiol Infect. 2020. Epub 2020/08/22. doi:
- 748 10.1016/j.cmi.2020.08.014. PubMed PMID: 32822881; PubMed Central PMCID:
- 749 PMCPMC7434422.
- 750 62. Ribeiro VST, Telles JP, Tuon FF. Concerns about COVID-19 and tuberculosis in Brazil:
- Social and public health impacts. Enfermedades Infecciosas y Microbiología Clínica. 2020. doi:
 https://doi.org/10.1016/j.eimc.2020.08.013.
- 753 63. Chandir S, Siddiqi DA, Mehmood M, Setayesh H, Siddique M, Mirza A, et al. Impact of
- 754 COVID-19 pandemic response on uptake of routine immunizations in Sindh, Pakistan: An
- analysis of provincial electronic immunization registry data. Vaccine. 2020;38(45):7146-55. doi:
 https://doi.org/10.1016/j.vaccine.2020.08.019.
- https://doi.org/10.1016/j.vaccine.2020.08.019.
 64. Glaziou P. Predicted impact of the COVID-19 pander
- Glaziou P. Predicted impact of the COVID-19 pandemic on global tuberculosis deaths in
 medRxiv. 2020:2020.04.28.20079582. doi: 10.1101/2020.04.28.20079582.

759 65. McOuaid CF, McCreesh N, Read JM, Sumner T, Houben RMGJ, White RG, et al. The 760 potential impact of COVID-19-related disruption on tuberculosis burden. European Respiratory 761 Journal. 2020;56(2):2001718. doi: 10.1183/13993003.01718-2020. 762 66. Cilloni L, Fu H, Vesga JF, Dowdy D, Pretorius C, Ahmedov S, et al. The potential 763 impact of the COVID-19 pandemic on the tuberculosis epidemic a modelling analysis. 764 EClinicalMedicine. 2020;28:100603. Epub 2020/11/03. doi: 10.1016/j.eclinm.2020.100603. 765 PubMed PMID: 33134905; PubMed Central PMCID: PMCPMC7584493. 766 Hogan AB, Jewell BL, Sherrard-Smith E, Vesga JF, Watson OJ, Whittaker C, et al. 67. 767 Potential impact of the COVID-19 pandemic on HIV, tuberculosis, and malaria in low-income 768 and middle-income countries: a modelling study. Lancet Glob Health. 2020;8(9):e1132-e41. doi: 769 10.1016/s2214-109x(20)30288-6. PubMed PMID: 32673577. 770 Cox V, Wilkinson L, Grimsrud A, Hughes J, Reuter A, Conradie F, et al. Critical changes 68. 771 to services for TB patients during the COVID-19 pandemic. The International Journal of 772 Tuberculosis and Lung Disease. 2020;24(5):542-4. doi: 10.5588/ijtld.20.0205. 773 774 69. Malik AA, Safdar N, Chandir S, Khan U, Khowaja S, Riaz N, et al. Tuberculosis control 775 and care in the era of COVID-19. Health Policy and Planning. 2020;35(8):1130-2. doi: 776 10.1093/heapol/czaa109. 777 Bell D, Hansen KS, Kiragga AN, Kambugu A, Kissa J, Mbonye AK. Predicting the 70. 778 Impact of COVID-19 and the Potential Impact of the Public Health Response on Disease Burden 779 in Uganda. Am J Trop Med Hyg. 2020;103(3):1191-7. doi: 10.4269/ajtmh.20-0546. PubMed 780 PMID: 32705975. 781 71. Guerra CA, Tresor Donfack O, Motobe Vaz L, Mba Nlang JA, Nze Nchama LO, Mba 782 Eyono JN, et al. Malaria vector control in sub-Saharan Africa in the time of COVID-19: no room 783 for complacency. BMJ Glob Health. 2020;5(9). doi: 10.1136/bmjgh-2020-003880. PubMed 784 PMID: 32938611. 785 Rogerson SJ, Beeson JG, Laman M, Poespoprodjo JR, William T, Simpson JA, et al. 72. 786 Identifying and combating the impacts of COVID-19 on malaria. BMC Med. 2020;18(1):239. 787 doi: 10.1186/s12916-020-01710-x. PubMed PMID: 32727467. 788 Mejia R, Hotez P, Bottazzi ME. Global COVID-19 Efforts as the Platform to Achieving 73. 789 the Sustainable Development Goals. Curr Trop Med Rep. 2020:1-5. doi: 10.1007/s40475-020-790 00209-y. PubMed PMID: 32844081. 791 Robinson EF, Moulder JK, Zerden ML, Miller AM, Zite NB. Preserving and advocating 74. 792 for essential care for women during the coronavirus disease 2019 pandemic. Am J Obstet 793 Gynecol. 2020;223(2):219-20.e1. doi: 10.1016/j.ajog.2020.05.022. PubMed PMID: 32405073. 794 Nghochuzie NN, Olwal CO, Udoakang AJ, Amenga-Etego LN, Amambua-Ngwa A. 75. 795 Pausing the Fight Against Malaria to Combat the COVID-19 Pandemic in Africa: Is the Future 796 of Malaria Bleak? Front Microbiol. 2020;11:1476. doi: 10.3389/fmicb.2020.01476. PubMed 797 PMID: 32625198. 798 76. Weiss DJ, Bertozzi-Villa A, Rumisha SF, Amratia P, Arambepola R, Battle KE, et al. 799 Indirect effects of the COVID-19 pandemic on malaria intervention coverage, morbidity, and 800 mortality in Africa: a geospatial modelling analysis. Lancet Infect Dis. 2020. doi: 801 10.1016/s1473-3099(20)30700-3. PubMed PMID: 32971006. 802 Torres K, Alava F, Soto-Calle V, Llanos-Cuentas A, Rodriguez H, Llacsahuanga L, et al. 77. 803 Malaria Situation in the Peruvian Amazon during the COVID-19 Pandemic. Am J Trop Med 804 Hyg. 2020. doi: 10.4269/ajtmh.20-0889. PubMed PMID: 32885776.

805 78. Buonsenso D, Cinicola B, Kallon MN, Iodice F. Child Healthcare and Immunizations in

806 Sub-Saharan Africa During the COVID-19 Pandemic. Front Pediatr. 2020;8:517. doi:

807 10.3389/fped.2020.00517. PubMed PMID: 32850565.

- 808 79. Beshir KB, Grignard L, Hajissa K, Mohammed A, Nurhussein AM, Ishengoma DS, et al.
- 809 Emergence of Undetectable Malaria Parasites: A Threat under the Radar amid the COVID-19
- Pandemic? Am J Trop Med Hyg. 2020;103(2):558-60. doi: 10.4269/ajtmh.20-0467. PubMed
 PMID: 32553046.
- 812 80. Chanda-Kapata P, Kapata N, Zumla A. COVID-19 and malaria: A symptom screening 813 challenge for malaria endemic countries. Int J Infect Dis. 2020;94:151-3. doi:
- 814 10.1016/j.ijid.2020.04.007. PubMed PMID: 32344326.
- 815 81. Zawawi A, Alghanmi M, Alsaady I, Gattan H, Zakai H, Couper K. The impact of

816 COVID-19 pandemic on malaria elimination. Parasite Epidemiol Control. 2020:e00187. doi:

817 10.1016/j.parepi.2020.e00187. PubMed PMID: 33102823.

- 818 82. Bull-Otterson L, Gray EB, Budnitz DS, Strosnider HM, Schieber LZ, Courtney J, et al.
- 819 Hydroxychloroquine and Chloroquine Prescribing Patterns by Provider Specialty Following
- 820 Initial Reports of Potential Benefit for COVID-19 Treatment United States, January-June 2020.

MMWR Morb Mortal Wkly Rep. 2020;69(35):1210-5. doi: 10.15585/mmwr.mm6935a4.
PubMed PMID: 32881845.

- 823 83. Mvumbi DM. Mass intake of hydroxychloroquine or chloroquine in the present context
- 824 of the Covid-19 outbreak: Possible consequences in endemic malaria settings. Med Hypotheses.
- 825 2020;143:109912. doi: 10.1016/j.mehy.2020.109912. PubMed PMID: 32498009.
- 826 84. Abena PM, Decloedt EH, Bottieau E, Suleman F, Adejumo P, Sam-Agudu NA, et al.
- 827 Chloroquine and Hydroxychloroquine for the Prevention or Treatment of COVID-19 in Africa:
- 828 Caution for Inappropriate Off-label Use in Healthcare Settings. Am J Trop Med Hyg.
- 829 2020;102(6):1184-8. doi: 10.4269/ajtmh.20-0290. PubMed PMID: 32323646.
- 830 85. Cox S. To dispense or not to dispense: Lessons to be learnt from ethical challenges faced
- by pharmacists in the COVID-19 pandemic. Dev World Bioeth. 2020. doi: 10.1111/dewb.12284.
- 832 PubMed PMID: 32844516.
- 833 86. Rodriguez-Valero N, Vera I, Torralvo MR, De Alba T, Ferrer E, Camprubi D, et al.
- 834 Malaria prophylaxis approach during COVID-19 pandemic. Travel Med Infect Dis.
- 835 2020:101716. doi: 10.1016/j.tmaid.2020.101716. PubMed PMID: 32360423.
- 836 87. Starrs AM, Ezeh AC, Barker G, Basu A, Bertrand JT, Blum R, et al. Accelerate progress-
- 837 sexual and reproductive health and rights for all: report of the Guttmacher-Lancet Commission.
- 838 Lancet. 2018;391(10140):2642-92. Epub 2018/05/14. doi: 10.1016/S0140-6736(18)30293-9.
- 839 PubMed PMID: 29753597.
- 840 88. Roberton T, Carter ED, Chou VB, Stegmuller AR, Jackson BD, Tam Y, et al. Early
- 841 estimates of the indirect effects of the COVID-19 pandemic on maternal and child mortality in
- 842 low-income and middle-income countries: a modelling study. Lancet Glob Health.
- 843 2020;8(7):e901-e8. PubMed PMID: 32405459.
- 844 89. Riley T, Sully E, Ahmed Z, Biddlecom A. Estimates of the Potential Impact of the
- 845 COVID-19 Pandemic on Sexual and Reproductive Health In Low- and Middle-Income
- 846 Countries. Int Perspect Sex Reprod Health. 2020;46:73-6. Epub 2020/04/29. doi:
- 847 10.1363/46e9020. PubMed PMID: 32343244.
- 848 90. Dasgupta A, Kantorova V, Ueffing P. The impact of the COVID-19 crisis on meeting
- needs for family planning: a global scenario by contraceptive methods used. Gates Open Res.

- 850 2020;4:102. Epub 2020/12/19. doi: 10.12688/gatesopenres.13148.2. PubMed PMID: 33330836;
 851 PubMed Central PMCID: PMCPMC7720714.
- 852 91. Weinberger M, Hayes B, White J, Skibiak J. Doing Things Differently: What It Would
- 853 Take to Ensure Continued Access to Contraception During COVID-19. Glob Health Sci Pract.
- 854 2020;8(2):169-75. Epub 2020/06/21. doi: 10.9745/GHSP-D-20-00171. PubMed PMID:
- 855 32561528; PubMed Central PMCID: PMCPMC7326519.
- Purdy C. How will COVID-19 affect global access to contraceptives—and what can wedo about it? Devex. 2020.
- Marie Stopes International (MSI). Resilience, adaptation and action. MSI's response to
 COVID-19. MSI, August, 2020.
- 860 94. Siedner MJ, Kraemer JD, Meyer MJ, Harling G, Mngomezulu T, Gabela P, et al. Access 861 to primary healthcare during lockdown measures for COVID-19 in rural South Africa: an
- interrupted time series analysis. BMJ Open. 2020;10(10):e043763. doi: 10.1136/bmjopen-2020043763. PubMed PMID: 33020109.
- 864 95. Coombe J, Kong F, Bittleston H, Williams H, Tomnay J, Vaisey A, et al. The impact of
 865 COVID-19 on the reproductive health of people living in Australia: findings from an online
- 866 survey. medRxiv. 2020:2020.08.10.20172163. doi: 10.1101/2020.08.10.20172163.
- Shikuku DN, Nyaoke I, Gichuru S, Maina O, Eyinda M, Godia P, et al. Early indirect
 impact of COVID-19 pandemic on utilization and outcomes of reproductive, maternal, newborn,
 child and adolescent health services in Kenya. medRxiv. 2020:2020.09.09.20191247. doi:
- 870 10.1101/2020.09.09.20191247.
- 97. Wangamati CK, Sundby J. The ramifications of COVID-19 on maternal health in Kenya.
 872 Sex Reprod Health Matters. 2020;28(1):1804716. doi: 10.1080/26410397.2020.1804716.
 873 PubMed PMID: 32896231.
- 874 98. Skuster P, Khanal RC, Nyamato E. Relics of imperialism: US foreign policy on abortion
- in the COVID era. Sex Reprod Health Matters. 2020;28(3):1824319. doi:
- 876 10.1080/26410397.2020.1824319. PubMed PMID: 33048026.
- 877 99. Abdela SG, Berhanu AB, Ferede LM, van Griensven J. Essential Healthcare Services in
- the Face of COVID-19 Prevention: Experiences from a Referral Hospital in Ethiopia. Am J Trop
 Med Hyg. 2020;103(3):1198-200. doi: 10.4269/ajtmh.20-0464. PubMed PMID: 32762799.
- 880 100. Yuksel B, Ozgor F. Effect of the COVID-19 pandemic on female sexual behavior. Int J
- Gynaecol Obstet. 2020;150(1):98-102. doi: 10.1002/ijgo.13193. PubMed PMID: 32392400.
- 882 101. Caruso S, Rapisarda AMC, Minona P. Sexual activity and contraceptive use during social
- distancing and self-isolation in the COVID-19 pandemic. Eur J Contracept Reprod Health Care.
- 884 2020:1-4. doi: 10.1080/13625187.2020.1830965. PubMed PMID: 33044107.
- 885 102. Thomson-Glover R, Hamlett H, Weston D, Ashby J. Coronavirus (COVID-19) and
- 886 young people's sexual health. Sex Transm Infect. 2020;96(7):473-4. doi: 10.1136/sextrans-2020887 054699. PubMed PMID: 33077611.
- 888 103. Ahmed A. How the COVID-19 response is altering the legal and regulatory landscape on 889 abortion. J Law Biosci. 2020;7(1):lsaa012. doi: 10.1093/jlb/lsaa012. PubMed PMID: 32728459.
- 890 104. Fulcher IR, Neill S, Bharadwa S, Goldberg AB, Janiak E. State and federal abortion
- restrictions increase risk of COVID-19 exposure by mandating unnecessary clinic visits.
- Contraception. 2020. doi: 10.1016/j.contraception.2020.08.017. PubMed PMID: 32905791.
- 893 105. Gildner TE, Thayer ZM. Birth plan alterations among American women in response to
- 894 COVID-19. Health Expect. 2020;23(4):969-71. doi: 10.1111/hex.13077. PubMed PMID:
- 895 32449262.

It is made available under a CC-BY-NC-ND 4.0 International license .

- 896 106. Ashish K, Gurung R, Kinney MV, Sunny AK, Moinuddin M, Basnet O, et al. Effect of
- the COVID-19 pandemic response on intrapartum care, stillbirth, and neonatal mortality
- 898 outcomes in Nepal: a prospective observational study. The Lancet Global health.
- 899 2020;8(10):e1273-e81. Epub 2020/08/10. doi: 10.1016/S2214-109X(20)30345-4. PubMed
 900 PMID: 32791117.
- 901 107. Coxon K, Turienzo CF, Kweekel L, Goodarzi B, Brigante L, Simon A, et al. The impact
- 902 of the coronavirus (COVID-19) pandemic on maternity care in Europe. Midwifery.
- 903 2020;88:102779. doi: 10.1016/j.midw.2020.102779. PubMed PMID: 32600862.
- 904 108. Davis-Floyd R, Gutschow K, Schwartz DA. Pregnancy, Birth and the COVID-19
- 905 Pandemic in the United States. Med Anthropol. 2020;39(5):413-27. doi:
- 906 10.1080/01459740.2020.1761804. PubMed PMID: 32406755.
- 907 109. Graham WJ, Afolabi B, Benova L, Campbell OMR, Filippi V, Nakimuli A, et al.
- 908 Protecting hard-won gains for mothers and newborns in low-income and middle-income
- 909 countries in the face of COVID-19: call for a service safety net. BMJ Glob Health. 2020;5(6).
- 910 doi: 10.1136/bmjgh-2020-002754. PubMed PMID: 32499220.
- 911 110. Pallangyo E, Nakate MG, Maina R, Fleming V. The impact of covid-19 on midwives'
- practice in Kenya, Uganda and Tanzania: A reflective account. Midwifery. 2020;89:102775. doi:
 10.1016/j.midw.2020.102775. PubMed PMID: 32526597.
- 914 111. Rimmer MP, Al Wattar BH. Provision of obstetrics and gynaecology services during the
- 915 COVID-19 pandemic: a survey of junior doctors in the UK National Health Service. Bjog.
- 916 2020;127(9):1123-8. doi: 10.1111/1471-0528.16313. PubMed PMID: 32460422.
- 917 112. Rochelson B, Nimaroff M, Combs A, Schwartz B, Meirowitz N, Vohra N, et al. The care
- 918 of pregnant women during the COVID-19 pandemic response of a large health system in
- 919 metropolitan New York. J Perinat Med. 2020;48(5):453-61. doi: 10.1515/jpm-2020-0175.
- 920 PubMed PMID: 32432568.
- 921 113. Semaan A, Audet C, Huysmans E, Afolabi B, Assarag B, Banke-Thomas A, et al. Voices
- from the frontline: findings from a thematic analysis of a rapid online global survey of maternal
- and newborn health professionals facing the COVID-19 pandemic. BMJ Global Health.
- 924 2020;5(6):e002967. doi: 10.1136/bmjgh-2020-002967.
- 925 114. Benova L, Sarkar ND, Fasehun LO, Semaan A, Affun-Adegbulu C. A call to action:
- 926 Documenting and sharing solutions and adaptations in sexual, reproductive, maternal and
- newborn health care provision during the COVID-19 pandemic. Sex Reprod Health Matters.
- 928 2020:1-5. doi: 10.1080/26410397.2020.1838054. PubMed PMID: 33073726.
- 929 115. Bateson DJ, Lohr PA, Norman WV, Moreau C, Gemzell-Danielsson K, Blumenthal PD,
- 930 et al. The impact of COVID-19 on contraception and abortion care policy and practice:
- 931 experiences from selected countries. BMJ Sex Reprod Health. 2020;46(4):241-3. doi:
- 932 10.1136/bmjsrh-2020-200709. PubMed PMID: 32788180.
- 933 116. Cohen MA, Powell AM, Coleman JS, Keller JM, Livingston A, Anderson JR. Special
- ambulatory gynecologic considerations in the era of coronavirus disease 2019 (COVID-19) and
- 935 implications for future practice. Am J Obstet Gynecol. 2020;223(3):372-8. doi:
- 936 10.1016/j.ajog.2020.06.006. PubMed PMID: 32522513.
- 937 117. Ferreira-Filho ES, de Melo NR, Sorpreso ICE, Bahamondes L, Simões RDS, Soares-
- 938 Júnior JM, et al. Contraception and reproductive planning during the COVID-19 pandemic.
- 939 Expert Rev Clin Pharmacol. 2020;13(6):615-22. doi: 10.1080/17512433.2020.1782738. PubMed
- 940 PMID: 32538185.

- 941 118. Moreau C, Shankar M, Glasier A, Cameron S, Gemzell-Danielsson K. Abortion
- regulation in Europe in the era of COVID-19: a spectrum of policy responses. BMJ Sex Reprod
 Health. 2020. doi: 10.1136/bmjsrh-2020-200724. PubMed PMID: 33093040.
- 119. Jones RK, Lindberg L, Witwer E. COVID-19 Abortion Bans and Their Implications for
- 945 Public Health. Perspect Sex Reprod Health. 2020. doi: 10.1363/psrh.12139. PubMed PMID:
- 946 32408393.
- 947 120. Aiken ARA, Starling JE, Gomperts R, Tec M, Scott JG, Aiken CE. Demand for Self-
- 948 Managed Online Telemedicine Abortion in the United States During the Coronavirus Disease
- 949 2019 (COVID-19) Pandemic. Obstet Gynecol. 2020;136(4):835-7. doi:
- 950 10.1097/aog.000000000004081. PubMed PMID: 32701762.
- 951 121. Caruana-Finkel L. Abortion in the time of COVID-19: perspectives from Malta. Sex
- Reprod Health Matters. 2020;28(1):1780679. doi: 10.1080/26410397.2020.1780679. PubMed
 PMID: 32516072.
- 954 122. Cioffi A, Cioffi F, Rinaldi R. COVID-19 and abortion: The importance of guaranteeing a
- 955 fundamental right. Sex Reprod Healthc. 2020;25:100538. doi: 10.1016/j.srhc.2020.100538.
 956 PubMed PMID: 32534228.
- 957 123. Aiken ARA, Starling JE, Gomperts R, Scott JG, Aiken C. Demand for Self-Managed
- 958 Online Telemedicine Abortion in Eight European Countries During the COVID-19 Pandemic: A
- 959 Regression Discontinuity Analysis. medRxiv. 2020:2020.09.15.20195222. doi:
- 960 10.1101/2020.09.15.20195222.
- 124. Erlank CP, Lord J, Church K. Early medical abortion using telemedicine acceptability
 to patients. medRxiv. 2020:2020.11.11.20229377. doi: 10.1101/2020.11.11.20229377.
- 963 125. Nagata JM, Seligman HK, Weiser SD. Perspective: The Convergence of Coronavirus
- Disease 2019 (COVID-19) and Food Insecurity in the United States. Adv Nutr. 2020. doi:
 10.1093/advances/nmaa126. PubMed PMID: 32970098.
- Kalu B. COVID-19 in Nigeria: a disease of hunger. Lancet Respir Med. 2020;8(6):556-7.
 doi: 10.1016/s2213-2600(20)30220-4. PubMed PMID: 32359414.
- 968 127. Brizi A, Biraglia A. "Do I have enough food?" How need for cognitive closure and
- 969 gender impact stockpiling and food waste during the COVID-19 pandemic: A cross-national
- study in India and the United States of America. Pers Individ Dif. 2021;168:110396. doi:
- 971 10.1016/j.paid.2020.110396. PubMed PMID: 32982000.
- 972 128. Heck S, Campos H, Barker I, Okello JJ, Baral A, Boy E, et al. Resilient agri-food
- 973 systems for nutrition amidst COVID-19: evidence and lessons from food-based approaches to
- 974 overcome micronutrient deficiency and rebuild livelihoods after crises. Food Secur.
- 975 2020;12(4):823-30. doi: 10.1007/s12571-020-01067-2. PubMed PMID: 32839664.
- 976 129. Kabir M, Saqib MAN, Zaid M, Ahmed H, Afzal MS. COVID-19, economic impact and
- 977 child mortality: A global concern. Clin Nutr. 2020;39(7):2322-3. doi:
- 978 10.1016/j.clnu.2020.05.027. PubMed PMID: 32499056.
- 979 130. Lobascio F, Caccialanza R, Monaco T, Cereda E, Secondino S, Masi S, et al. Providing
- 980 nutritional care to cancer patients during the COVID-19 pandemic: an Italian perspective.
- 981 Support Care Cancer. 2020;28(9):3987-9. doi: 10.1007/s00520-020-05557-z. PubMed PMID:
 982 32495030.
- 983 131. Masonbrink AR, Hurley E. Advocating for Children During the COVID-19 School
- 984 Closures. Pediatrics. 2020;146(3). doi: 10.1542/peds.2020-1440. PubMed PMID: 32554517.
- 985 132. Mayurasakorn K, Pinsawas B, Mongkolsucharitkul P, Sranacharoenpong K, Damapong
- 986 SN. School closure, COVID-19 and lunch programme: Unprecedented undernutrition crisis in

It is made available under a CC-BY-NC-ND 4.0 International license .

- 987 low-middle income countries. J Paediatr Child Health. 2020;56(7):1013-7. doi:
- 988 10.1111/jpc.15018. PubMed PMID: 32619327.
- 989 Akseer N, Kandru G, Keats EC, Bhutta ZA. COVID-19 pandemic and mitigation 133.
- 990 strategies: implications for maternal and child health and nutrition. Am J Clin Nutr.
- 991 2020;112(2):251-6. doi: 10.1093/ajcn/ngaa171. PubMed PMID: 32559276.
- 992 Panthi B, Khanal P, Dahal M, Maharjan S, Nepal S. An urgent call to address the 134.
- 993 nutritional status of women and children in Nepal during COVID-19 crises. Int J Equity Health.
- 994 2020;19(1):87. doi: 10.1186/s12939-020-01210-7. PubMed PMID: 32503613.
- 995 Hakeem R, Sheikh MA. Beyond transmission: Dire need for integration of nutrition 135.
- 996 interventions in COVID-19 pandemic-response strategies in Developing Countries like Pakistan.
- 997 Pak J Med Sci. 2020;36(Covid19-s4):S85-s9. doi: 10.12669/pjms.36.COVID19-S4.2784.
- 998 PubMed PMID: 32582320.
- 999 Sidor A, Rzymski P. Dietary Choices and Habits during COVID-19 Lockdown: 136.
- 1000 Experience from Poland. Nutrients. 2020;12(6). doi: 10.3390/nu12061657. PubMed PMID:
- 1001 32503173.
- 1002 137. Bhatia V, Mandal P, Satyanarayana S, Aditama T, Sharma M. Mitigating the impact of
- 1003 the COVID-19 pandemic on progress towards ending tuberculosis in the WHO South-East Asia
- 1004 Region. WHO South-East Asia Journal of Public Health. 2020;9(2):95-9. doi: 10.4103/2224-1005 3151.294300.
- 1006 138. Dieppe A, Kose MA. The Global Productivity Slump: What Policies to Rekindle?
- 1007 (https://www.brookings.edu/research/the-global-productivity-slump-what-policies-to-
- 1008 rekindle/#footnote-2). Washington DC: 2020.
- 1009 139. Naidoo R, Fisher B. Reset Sustainable Development Goals for a pandemic world. Nature.
- 1010 2020;583(7815):198-201. Epub 2020/07/08. doi: 10.1038/d41586-020-01999-x. PubMed PMID:
- 1011 32632244.
- 1012 140. Hall KS, Samari G, Garbers S, Casey SE, Diallo DD, Orcutt M, et al. Centring sexual and 1013 reproductive health and justice in the global COVID-19 response. Lancet.
- 1014 2020;395(10231):1175-7. PubMed PMID: 32278371.
- 1015 141. UNFPA, Avenir Health, Johns Hopkins University, Victoria University. Impact of the
- 1016 COVID-19 Pandemic on Family Planning and Ending Gender-based Violence, Female Genital
- 1017 Mutilation and Child Marriage. Pandemic threatens achievement of the Transformative Results
- 1018 committed to by UNFPA. https://www.unfpa.org/sites/default/files/resource-pdf/COVID-
- 1019 19_impact_brief_for_UNFPA_24_April_2020_1.pdf: UNFPA, April, 2020.
- 1020 142. Kumar N. COVID 19 era: a beginning of upsurge in unwanted pregnancies, unmet need 1021
- for contraception and other women related issues. Eur J Contracept Reprod Health Care.
- 1022 2020;25(4):323-5. doi: 10.1080/13625187.2020.1777398. PubMed PMID: 32567961.
- 1023 Bekker LG, Alleyne G, Baral S, Cepeda J, Daskalakis D, Dowdy D, et al. Advancing 143.
- 1024 global health and strengthening the HIV response in the era of the Sustainable Development
- 1025 Goals: the International AIDS Society-Lancet Commission. Lancet. 2018;392(10144):312-58.
- Epub 2018/07/24. doi: 10.1016/s0140-6736(18)31070-5. PubMed PMID: 30032975; PubMed 1026 1027 Central PMCID: PMCPMC6323648.
- 1028 Zuckerman G, McKay B. How HIV Research Laid the Foundation for COVID Vaccines. 144.
- 1029 Wall Street Journal. 2020.
- 1030 145. amfAR. The Broad Benefits of AIDS Research. New York, NY: 2020.
- 1031 146. WHO. TB and HIV, and other comorbidities 2020. Available from:
- 1032 https://www.who.int/tb/areas-of-work/tb-

hiv/en/#:~:text=TB% 20is% 20the% 20most% 20common.HIV% 2Dassociated% 20TB% 20in% 202

1033

1034

018.

1035 147. Bonn M, Palayew A, Bartlett S, Brothers TD, Touesnard N, Tyndall M. Addressing the 1036 Syndemic of HIV, Hepatitis C, Overdose, and COVID-19 Among People Who Use Drugs: The 1037 Potential Roles for Decriminalization and Safe Supply. Journal of studies on alcohol and drugs. 1038 2020;81(5):556-60. Epub 2020/10/09. PubMed PMID: 33028465. 1039 Pérez-Escamilla R, Cunningham K, Moran VH. COVID-19 and maternal and child food 148. 1040 and nutrition insecurity: a complex syndemic. Maternal & child nutrition. 2020;16(3):e13036. 1041 Epub 2020/05/28. doi: 10.1111/mcn.13036. PubMed PMID: 32458574; PubMed Central 1042 PMCID: PMCPMC7267083. 1043 149. Poteat T, Millett GA, Nelson LE, Beyrer C. Understanding COVID-19 risks and 1044 vulnerabilities among black communities in America: the lethal force of syndemics. Annals of 1045 epidemiology. 2020;47:1-3. Epub 2020/05/19. doi: 10.1016/j.annepidem.2020.05.004. PubMed 1046 PMID: 32419765; PubMed Central PMCID: PMCPMC7224650. 1047 Venkatesh V. Impacts of COVID-19: A research agenda to support people in their fight. 150. 1048 International journal of information management. 2020;55:102197. Epub 2020/08/25. doi: 1049 10.1016/j.ijinfomgt.2020.102197. PubMed PMID: 32836648; PubMed Central PMCID: 1050 PMCPMC7368151. 1051 Queiroz MM, Ivanov D, Dolgui A, Fosso Wamba S. Impacts of epidemic outbreaks on 151. 1052 supply chains: mapping a research agenda amid the COVID-19 pandemic through a structured 1053 literature review. Annals of operations research. 2020:1-38. Epub 2020/08/25. doi: 1054 10.1007/s10479-020-03685-7. PubMed PMID: 32836615; PubMed Central PMCID: 1055 PMCPMC7298926. 1056 Oyebode O, Ramsay SE, Brayne C. Public health research in the UK to understand and 152. 1057 mitigate the impact of COVID-19 and COVID-19 response measures. Journal of epidemiology 1058 and community health. 2020. Epub 2020/10/09. doi: 10.1136/jech-2020-214997. PubMed PMID: 1059 33028615. 1060 153. Shiau S, Krause KD, Valera P, Swaminathan S, Halkitis PN. The Burden of COVID-19 1061 in People Living with HIV: A Syndemic Perspective. AIDS Behav. 2020;24(8):2244-9. Epub 2020/04/19. doi: 10.1007/s10461-020-02871-9. PubMed PMID: 32303925; PubMed Central 1062 1063 PMCID: PMCPMC7165075. 1064 154. Yadav UN, Rayamajhee B, Mistry SK, Parsekar SS, Mishra SK. A Syndemic Perspective 1065 on the Management of Non-communicable Diseases Amid the COVID-19 Pandemic in Low-1066 and Middle-Income Countries. Frontiers in public health. 2020;8:508. Epub 2020/10/27. doi: 1067 10.3389/fpubh.2020.00508. PubMed PMID: 33102414; PubMed Central PMCID: 1068 PMCPMC7545493. 1069 Hollingsworth TD. Controlling infectious disease outbreaks: Lessons from mathematical 155. 1070 modelling. J Public Health Policy. 2009;30(3):328-41. Epub 2009/10/07. doi: 10.1057/jphp.2009.13. PubMed PMID: 19806073; PubMed Central PMCID: 1071 1072 PMCPMC7099230. 1073 Viboud C, Sun K, Gaffey R, Ajelli M, Fumanelli L, Merler S, et al. The RAPIDD ebola 156. 1074 forecasting challenge: Synthesis and lessons learnt. Epidemics. 2018;22:13-21. Epub 1075 2017/09/30. doi: 10.1016/j.epidem.2017.08.002. PubMed PMID: 28958414; PubMed Central 1076 PMCID: PMCPMC5927600. 1077 157. Thompson RN, Hollingsworth TD, Isham V, Arribas-Bel D, Ashby B, Britton T, et al. 1078 Key questions for modelling COVID-19 exit strategies. Proc Biol Sci.

It is made available under a CC-BY-NC-ND 4.0 International license .

- 1079 2020;287(1932):20201405. Epub 2020/08/13. doi: 10.1098/rspb.2020.1405. PubMed PMID:
- 1080 32781946; PubMed Central PMCID: PMCPMC7575516.
- 1081 158. Development. OfECa. Health Care Resources: Hospital Beds
- 1082 (https://stats.oecd.org/index.aspx?queryid=30183). 2020.
- 1083 159. Scheffler R. The Labour market for human resources for health in low- and middle-
- 1084 income countries (https://www.who.int/hrh/resources/Observer11_WEB.pdf). Geneva: 2012.
- 1085 160. WHO. Global Health Observatory data repository
- 1086 (https://apps.who.int/gho/data/node.main.MHHR?lang=en). Geneva: 2019.
- 1087 161. Carias C, Pawaskar M, Nyaku M, Conway JH, Roberts CS, Finelli L, et al. Potential
- 1088 impact of COVID-19 pandemic on vaccination coverage in children: A case study of measles-
- 1089 containing vaccine administration in the United States (US). Vaccine. 2020. Epub 2020/12/19.
- doi: 10.1016/j.vaccine.2020.11.074. PubMed PMID: 33334618; PubMed Central PMCID:
 PMCPMC7723783.
- 1092 162. Hartnett KP, Kite-Powell A, DeVies J, Coletta MA, Boehmer TK, Adjemian J, et al.
- 1093 Impact of the COVID-19 Pandemic on Emergency Department Visits United States, January 1,
- 1094 2019-May 30, 2020. MMWR Morb Mortal Wkly Rep. 2020;69(23):699-704. Epub 2020/06/12.
- 1095 doi: 10.15585/mmwr.mm6923e1. PubMed PMID: 32525856; PubMed Central PMCID:
- 1096 PMCPMC7315789 Journal Editors form for disclosure of potential conflicts of interest. No1097 potential conflicts of interest were disclosed.
- 1098 163. Dyer O. Covid-19: Pandemic is having "severe" impact on non-communicable disease
- 1099 care, WHO survey finds. BMJ. 2020;369:m2210. Epub 2020/06/05. doi: 10.1136/bmj.m2210.
- 1100 PubMed PMID: 32493728.
- 1101 164. Strully K, Yang TC, Liu H. Regional variation in COVID-19 disparities: connections
- 1102 with immigrant and Latinx communities in U.S. counties. Ann Epidemiol. 2021;53:56-62 e2.
- 1103 Epub 2020/09/15. doi: 10.1016/j.annepidem.2020.08.016. PubMed PMID: 32927056; PubMed
- 1104 Central PMCID: PMCPMC7485497.
- 1105 165. Noman AHM, Griffiths MD, Pervin S, Ismail MN. The detrimental effects of the
- 1106 COVID-19 pandemic on domestic violence against women. J Psychiatr Res. 2020;134:111-2.
- 1107 Epub 2021/01/01. doi: 10.1016/j.jpsychires.2020.12.057. PubMed PMID: 33383493.
- 1108 166. Wang Y, Kala MP, Jafar TH. Factors associated with psychological distress during the
- 1109 coronavirus disease 2019 (COVID-19) pandemic on the predominantly general population: A
- 1110 systematic review and meta-analysis. PLoS One. 2020;15(12):e0244630. Epub 2020/12/29. doi:
- 1111 10.1371/journal.pone.0244630. PubMed PMID: 33370404.
- 1112
- 1113
- 1114
- 1115
- 1116
- 1117
- 1118
- 1119
- 1120
- 1121
- 1122
- 1123
- 1124

It is made available under a CC-BY-NC-ND 4.0 International license .

1125

1126 APPENDIX: Search Strategies

- 1127
- 1128 **HIV**
- 1129 ((("COVID-19"[tw] OR "COVID 19"[tw] OR "COVID19"[tw] OR "COVID2019"[tw] OR
- 1130 "COVID 2019"[tw] OR "COVID-2019"[tw] OR "novel coronavirus"[tw] OR "new
- 1131 coronavirus"[tw] OR "novel corona virus"[tw] OR "new corona virus"[tw] OR "SARS-CoV-
- 1132 2"[tw] OR "SARSCoV2"[tw] OR "SARS-CoV2"[tw] OR "2019nCoV"[tw] OR "2019-
- 1133 nCoV"[tw] OR "2019 coronavirus"[tw] OR "2019 corona virus"[tw] OR "coronavirus disease
- 1134 2019"[tw] OR "severe acute respiratory syndrome coronavirus 2"[nm] OR "severe acute
- 1135 respiratory syndrome coronavirus 2"[tw] OR "sars-coronavirus-2"[tw] OR "coronavirus disease
- 1136 2019"[tw] OR "corona virus disease 2019"[tw])) AND (("2020/MM/DD"[PDAT] :
- 1137 "3000/MM/DD"[PDAT]))) AND ("HIV"[Mesh] OR "Acquired Immunodeficiency
- 1138 Syndrome"[Mesh] OR "HIV Infections"[Mesh] OR human immunodeficiency virus*[tw] OR
- acquired immunodeficiency syndrome*[tw] OR HIV*[tw] OR "AIDS"[tw] OR HIV1*[tw] OR
- 1140 HIV2*[tw])
- 1141

1142 Malnutrition

- 1143 ((("COVID-19"[tw] OR "COVID 19"[tw] OR "COVID19"[tw] OR "COVID2019"[tw] OR
- 1144 "COVID 2019"[tw] OR "COVID-2019"[tw] OR "novel coronavirus"[tw] OR "new
- 1145 coronavirus"[tw] OR "novel corona virus"[tw] OR "new corona virus"[tw] OR "SARS-CoV-
- 1146 2"[tw] OR "SARSCoV2"[tw] OR "SARS-CoV2"[tw] OR "2019nCoV"[tw] OR "2019-
- 1147 nCoV"[tw] OR "2019 coronavirus"[tw] OR "2019 corona virus"[tw] OR "coronavirus disease
- 1148 2019"[tw] OR "severe acute respiratory syndrome coronavirus 2"[nm] OR "severe acute
- 1149 respiratory syndrome coronavirus 2"[tw] OR "sars-coronavirus-2"[tw] OR "coronavirus disease
- 1150 2019"[tw] OR "corona virus disease 2019"[tw])) AND (("2020/MM/DD"[PDAT] :
- 1151 "3000/MM/DD"[PDAT]))) AND ("Infant nutrition disorders"[Mesh] OR "child nutrition
- disorders" [Mesh] OR "malnutrition" [Mesh] OR "thinness" [Mesh] OR "wasting syndrome"
- 1153 [Mesh] OR "undernutrition"[tw] OR undernourish*[tw] OR "chronic energy deficiency"[tw] OR
- 1154 "stunting"[tw] OR "wasting"[tw] OR "underweight"[tw] OR "thinness"[tw] OR micronutrient
- 1155 deficienc*[tw] OR vitamin deficienc*[tw] OR mineral deficienc*[tw])
- 1156

1157 <u>Malaria</u>

- 1158 ((("COVID-19"[tw] OR "COVID 19"[tw] OR "COVID19"[tw] OR "COVID2019"[tw] OR
- 1159 "COVID 2019"[tw] OR "COVID-2019"[tw] OR "novel coronavirus"[tw] OR "new
- 1160 coronavirus"[tw] OR "novel corona virus"[tw] OR "new corona virus"[tw] OR "SARS-CoV-
- 1161 2"[tw] OR "SARSCoV2"[tw] OR "SARS-CoV2"[tw] OR "2019nCoV"[tw] OR "2019-
- 1162 nCoV"[tw] OR "2019 coronavirus"[tw] OR "2019 corona virus"[tw] OR "coronavirus disease
- 1163 2019"[tw] OR "severe acute respiratory syndrome coronavirus 2"[nm] OR "severe acute
- 1164 respiratory syndrome coronavirus 2"[tw] OR "sars-coronavirus-2"[tw] OR "coronavirus disease
- 1165 2019"[tw] OR "corona virus disease 2019"[tw])) AND (("2020/MM/DD"[PDAT] :
- 1166 "3000/MM/DD"[PDAT]))) AND ("Malaria" [Mesh] OR "malaria" [tw] OR "plasmodium" [tw])
- 1167 1168 **TB**
- 1169 ((("COVID-19"[tw] OR "COVID 19"[tw] OR "COVID19"[tw] OR "COVID2019"[tw] OR
- 1170 "COVID 2019"[tw] OR "COVID-2019"[tw] OR "novel coronavirus"[tw] OR "new

It is made available under a CC-BY-NC-ND 4.0 International license .

- 1171 coronavirus"[tw] OR "novel corona virus"[tw] OR "new corona virus"[tw] OR "SARS-CoV-
- 1172 2"[tw] OR "SARSCoV2"[tw] OR "SARS-CoV2"[tw] OR "2019nCoV"[tw] OR "2019-
- 1173 nCoV"[tw] OR "2019 coronavirus"[tw] OR "2019 corona virus"[tw] OR "coronavirus disease
- 1174 2019"[tw] OR "severe acute respiratory syndrome coronavirus 2"[nm] OR "severe acute
- 1175 respiratory syndrome coronavirus 2"[tw] OR "sars-coronavirus-2"[tw] OR "coronavirus disease
- 1176 2019"[tw] OR "corona virus disease 2019"[tw])) AND (("2020/MM/DD"[PDAT] :
- 1177 "3000/MM/DD"[PDAT]))) AND ("Tuberculosis" [Mesh] OR "tuberculosis" [tw] OR "TB"[tw]
- 1178 OR mycobacter*[tw])
- 1179
- 1180 Sexual and Reproductive Health
- 1181 ((("COVID-19"[tw] OR "COVID 19"[tw] OR "COVID19"[tw] OR "COVID2019"[tw] OR
- 1182 "COVID 2019"[tw] OR "COVID-2019"[tw] OR "novel coronavirus"[tw] OR "new
- 1183 coronavirus"[tw] OR "novel corona virus"[tw] OR "new corona virus"[tw] OR "SARS-CoV-
- 1184 2"[tw] OR "SARSCoV2"[tw] OR "SARS-CoV2"[tw] OR "2019nCoV"[tw] OR "2019-
- 1185 nCoV"[tw] OR "2019 coronavirus"[tw] OR "2019 corona virus"[tw] OR "coronavirus disease
- 1186 2019"[tw] OR "severe acute respiratory syndrome coronavirus 2"[nm] OR "severe acute
- 1187 respiratory syndrome coronavirus 2"[tw] OR "sars-coronavirus-2"[tw] OR "coronavirus disease
- 1188 2019"[tw] OR "corona virus disease 2019"[tw])) AND (("2020/MM/DD"[PDAT] :
- 1189 "3000/MM/DD"[PDAT]))) AND ("Reproductive Health" [Mesh] OR "Reproductive Health
- 1190 Services" [Mesh] OR "maternal health" [Mesh] OR "maternal health services" [Mesh] OR
- 1191 "reproductive health"[tw] "maternal health"[tw] OR contracept*[tw] OR "family planning"[tw]
- 1192 OR "abortion"[tw] OR "post-abortion care"[tw] OR "unintended pregnancy"[tw] OR "unplanned
- 1193 pregnancy"[tw] OR "unwanted pregnancy"[tw])
- 1194
- 1195
- 1196
- 1197
- 1198